PEGylation of Niosomes by Elliott, John A.
University of South Florida
Scholar Commons
Graduate Theses and Dissertations Graduate School
11-16-2009
PEGylation of Niosomes
John A. Elliott
University of South Florida
Follow this and additional works at: http://scholarcommons.usf.edu/etd
Part of the American Studies Commons, Biomedical Engineering and Bioengineering Commons,
and the Chemical Engineering Commons
This Dissertation is brought to you for free and open access by the Graduate School at Scholar Commons. It has been accepted for inclusion in
Graduate Theses and Dissertations by an authorized administrator of Scholar Commons. For more information, please contact
scholarcommons@usf.edu.
Scholar Commons Citation
Elliott, John A., "PEGylation of Niosomes" (2009). Graduate Theses and Dissertations.
http://scholarcommons.usf.edu/etd/3448
 PEGylation of Niosomes 
 
 
 
 
by 
 
 
 
 
John A. Elliott 
 
 
 
 
 
 
A dissertation submitted in partial fulfillment 
of the requirements for the degree of 
Doctor of Philosophy 
Department of Chemical and Biomedical Engineering 
College of Engineering 
University of South Florida 
 
 
 
 
Co-Major Professor: Michael VanAuker, Ph.D. 
Co-Major Professor: Mark Jaroszeski, Ph.D. 
Joel Strom, M.D. 
Nathan Gallant, Ph.D. 
Ryan Toomey, Ph.D. 
Karl Muffly, Ph.D. 
John Wolan, Ph.D. 
 
 
 
Date of Approval: 
November 16, 2009 
 
 
 
Keywords: targeted drug delivery, polyethylene glycol, nanoparticle, liposome, 
inflammation 
 
© Copyright 2010 , John Elliott 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Dedication 
I would like to dedicate this document to my wife Jill and my two children Tyler 
and Claire as well as all those who have inspired me in the past and those who I hope to 
encourage making a positive impact on the scientific community. 
 
 
  
  
 
 
 
 
 
 
 
 
Acknowledgments 
I would like to acknowledge Dr. Brenda Flam and Dr. Elizabeth Hood for being 
great mentors and for all the encouragement and help I have received from them over the 
course of my research. A special acknowledgement is in order for all of my committee 
members and especially, Drs. VanAuker, Muffly and Strom for their guidance and 
support during this process. I would also like to acknowledge the faculty and staff at USF 
Health for the use of their facilities and all of the technical support they have provided. 
 
i 
 
 
 
Table of Contents 
List of Tables .................................................................................................................... iii 
List of Figures .................................................................................................................... iv 
Abstract ........................................................................................................................... viii 
1. Project Background ..................................................................................................1 
 1.1.0 Drug Delivery Introduction .........................................................................4 
  1.1.1 Basics of Pharmacokinetics .............................................................4 
  1.1.2 Compartment Models.......................................................................6 
 1.2.0 Introduction to the Cardiovascular System ..................................................8 
  1.2.1 Blood ................................................................................................8 
  1.2.2 Heart ...............................................................................................11 
  1.2.3 Circulation......................................................................................12 
 1.3.0 Cell Introduction ........................................................................................13 
  1.3.1 Endothelial Cells ............................................................................14 
  1.3.2 Endothelial Cell Mass Transport ...................................................16 
  1.3.3 Endocytosis ....................................................................................19 
 1.4.0 Cell Surface Receptors ...............................................................................20 
  1.4.1 Proteins ..........................................................................................24 
  1.4.2 Antibodies ......................................................................................24 
   1.4.2.1 Immunoglobulin G ........................................................26 
   1.4.2.2 Monoclonal Antibodies .................................................28 
  1.4.3 CD44 Receptor...............................................................................29 
  1.4.4 Intercellular Adhesion Molecule (ICAM) .....................................30 
  1.4.5 Vascular Cellular Adhesion Molecule (VCAM) ...........................31 
 1.5.0 Cytokines and Inflammation ......................................................................32 
 1.5.1 Tumor Necrosis Factor Alpha ........................................................33 
 1.5.2 Interleukin 1 ...................................................................................34 
 1.6.0 Cardiovascular Disease ..............................................................................34 
 
2. Construction and Characterization of Modified Vesicle Design ...........................37 
 2.1.0 Amphiphiles ...............................................................................................37 
 2.1.1 Non-Ionic Surfactants ....................................................................39 
 2.1.2 Cholesterol .....................................................................................40 
 2.2.0 Polyethylene Glycol ...................................................................................41 
 2.3.0 Molecule Synthesis ....................................................................................42 
 2.3.1 Functionalized Non-Ionic Surfactant .............................................43 
 2.3.2 Functionalized Cholesterol ............................................................46 
 2.4.0 Vesicle Synthesis .......................................................................................47 
ii 
 2.4.1 Thin Film Formation and Hydration ..............................................48 
 2.4.2 Vesicle Extrusion ...........................................................................48 
 2.4.3 Size Exclusion Chromatography  
 Introduction ....................................................................................49 
  2.4.3.1 SEC Volumetric Theory ..............................................50 
  2.4.3.2 SEC Methods ...............................................................51 
 2.4.4 Antibody Conjugation ....................................................................53 
 2.5.0 Vesicle Metrology ......................................................................................54 
 2.5.1 Thin Layer Chromatography Introduction .....................................54 
  2.5.1.1 Thin Layer Chromatography Methods.........................55 
  2.5.1.2 Thin Layer Chromatography Results ...........................57 
 2.5.2 Fluorescent Microscopy .................................................................58 
 2.5.3 Flow Cytometry .............................................................................61 
 2.5.4 Transmission Electron Microscopy ...............................................65 
 2.5.5 Dynamic Light Scattering ..............................................................69 
 
3. Evaluation of Receptor-Conjugated Vesicles ........................................................73 
 3.1.0 Cell Culture ................................................................................................73 
 3.2.0 Fixed Cell Binding .....................................................................................74 
 3.3.0 Live Cell Binding .......................................................................................77 
  3.3.1 Multiwell Plate Experiments..........................................................77 
  3.3.2 Confocal Laser Scanning Microscopy ...........................................80 
  3.3.3 Transmission Electron Microscopy ...............................................89 
 3.4.0 pH Sensitive Dye Study .............................................................................92 
 3.5.0 Vesicle Binding in Flow ............................................................................95 
 
4.  Enhancement of the Modified Vesicle Designs for Targeted  
 Delivery in Vivo ....................................................................................................97 
 4.1.0 Multi Well Plate Imaging...........................................................................97 
 4.2.0 Phantom Mouse Imaging ...........................................................................99 
 
5. Discussion and Future Direction ..........................................................................103 
 5.1.0 Vesicle Design and Manufacturing ..........................................................103 
 5.2.0 Experimental Conclusions .......................................................................107 
 5.3.0 Future Directions .....................................................................................109 
 
References  .......................................................................................................................111 
Bibliography ....................................................................................................................125 
Appendices  ......................................................................................................................127 
 Appendix A: Transmission Electron Microscopy Notes ...................................128 
  
About The Author .................................................................................................. End Page 
 
iii 
 
 
 
 
List of Tables 
Table 1.0  Project Aims.................................................................................................3 
Table 1.1 Physical Properties of Blood ........................................................................9 
Table 1.2 Blood Cell Types .......................................................................................10 
Table 1.3 Endothelial Transport Equations [36] ........................................................17 
Table 1.4 Integral Membrane Protein Types .............................................................21 
Table 1.5 Common Cell Adhesion Molecules (CAMs) .............................................22 
Table 1.6 Human Immunoglobulin Types .................................................................26 
Table 2.0 Immuno-niosome Materials .......................................................................43 
Table 2.1 TLC Materials ............................................................................................55 
Table 2.2 5% PEG Sample Event Population ............................................................63 
Table 2.3 5% PEG Sample Median Distribution .......................................................63 
Table 2.4 10% Functionalized Cholesterol Median Population ................................64 
Table 2.5 Transmission Electron Microscopy Materials ...........................................65 
Table 3.0 Static Binding Results ................................................................................77 
Table 3.1 Injury Binding Results ...............................................................................83 
  
iv 
 
 
 
 
List of Figures 
Figure 1.0 PEGylated Immuno-niosome .......................................................................3 
Figure 1.1 Simple Compartmental Model .....................................................................7 
Figure 1.2 Endothelial Cell on Aortic Valve (arterial) ................................................15 
Figure 1.3 Immunoglobulin G (IgG) ...........................................................................28 
Figure 1.4 CD44 Genomic Sequence and Receptor Structure [82,83] .......................29 
Figure 1.5 ICAM-1 ......................................................................................................31 
Figure 1.6 VCAM-1 ....................................................................................................32 
Figure 2.0 Hydrodynamic Shell of a Surfactant Molecule ..........................................38 
Figure 2.1 Molecules: Span 60 and Tween 61  ...........................................................40 
Figure 2.2 Cholesterol .................................................................................................40 
Figure 2.3 Polyethylene Glycol (PEG)........................................................................41 
Figure 2.4 PEGylated Surfactant Synthesis ................................................................45 
Figure 2.5  Functionalized Cholesterol Synthesis ........................................................47 
Figure 2.6 Size Exclusion Chromatography................................................................50 
Figure 2.7 Size Exclusion Chromatography Elution Profile .......................................51 
Figure 2.8  Elution Profile from 2 ml Sample Size .....................................................52 
Figure 2.9 Elution Profile from 500 ul Sample Size ...................................................53 
Figure 2.10 Antibody Conjugation ................................................................................54 
Figure 2.11 TLC Image Analysis ..................................................................................57 
Figure 2.12 Atorvastatin Standards ...............................................................................58 
v 
Figure 2.13 Jablonski Diagram .....................................................................................59 
Figure 2.14 PEGylated FITC Conjugated Immuno-niosomes ......................................60 
Figure 2.15 FITC Conjugated Immuno-niosomes Using Functionalized 
Cholesterol .................................................................................................60 
Figure 2.16 5% PEG Sample Forward Scatter Distribution ..........................................62 
Figure 2.17 5% PEG Sample Particle Size Distribution ...............................................62 
Figure 2.18 5% PEG Sample Dynamic Light Scattering Data ......................................63 
Figure 2.19 10% Functionalized Cholesterol Forward Scatter Distribution .................64 
Figure 2.20 10% Functionalized Cholesterol Sample Dynamic Light Scattering 
Data ............................................................................................................65 
Figure 2.21 TEM of Bulk Solution ...............................................................................67 
Figure 2.22 TEM of Extruded 5% PEGylated Niosomes .............................................68 
Figure 2.23 TEM of 5% PEGylated FeO-Loaded Niosomes ........................................68 
Figure 2.24 Dynamic Light Scattering ..........................................................................69 
Figure 2.25 Niosome Sample Correlation Data ............................................................71 
Figure 2.26 Data from Stability Comparison Study on Day90 .....................................72 
Figure 3.0 Fixed Cell Binding: 10% Tween Fluorescein-loaded 
  IN (CD44, KM201) ....................................................................................76 
Figure 3.1 Fixed Cell Binding: 5% PEG Fluorescein-loaded 
  IN (CD44, KM201) ....................................................................................76 
Figure 3.2 Nonspecific Binding Results ......................................................................79 
Figure 3.3 Live Binding Performances .......................................................................80 
Figure 3.4 One Hour Scratch Injury ICAM (200X Magnification) ............................82 
Figure 3.5 Graph of Fluorescent Intensity from Region of Interest 1 .........................82 
Figure 3.6 Injury Model Region of Interest (200X Magnification) ............................83 
vi 
Figure 3.7 (A) 4 Hour PEGylated CD44 Immuno-niosomes, (B) Control, 4 
Hour PEGylated CD44 Immuno-niosomes, (630X Magnification) ..........85 
Figure 3.8 (A) 3 Hour PEGylated CD44 Immuno-niosomes, (B) Control, 3 
Hour PEGylated CD44 Immuno-niosomes, (630X Magnification) ..........85 
Figure 3.9 (A) 2 Hour PEGylated CD44 Immuno-niosomes, (B) Control, 2 
Hour PEGylated CD44 Immuno-niosomes, (630X Magnification) ..........86 
Figure 3.10 (A) 1 Hour PEGylated CD44 Immuno-niosomes, (B) Control, 1 
Hour PEGylated CD44 Immuno-niosomes, (630X Magnification) ..........86 
Figure 3.11 (A-D) Z-stack of the 1-4 Hour PEGylated CD44 Immuno-
niosomes, (630X Magnification) ...............................................................87 
Figure 3.12 (A) 4 Hour PEGylated VCAM-1 Immuno-niosomes, (B) Control, 4 
Hour PEGylated VCAM-1 Immuno-niosomes,  
  (630X Magnification) ................................................................................88 
Figure 3.13 (A) 4 Hour ICAM Cholesterol Immuno-niosomes, (B) Control, 4 
Hour ICAM Cholesterol Immuno-niosomes (630X Magnification) .........89 
Figure 3.14 Gold Loaded, Internalized Immuno-niosomes ..........................................91 
Figure 3.15 Gold Loaded Immuno-niosome Bound to Cell Membrane .......................92 
Figure 3.16 Fluorescence Spectra of 1 μM SNARF-4 in PBS, pH 5.45 to 7.2 .............93 
Figure 3.17  Spectrum of SNARF-4 Loaded Span 60 Niosomes at pH 7.2 ...................94 
Figure 3.18 Spectrum of Cholesterol ............................................................................95 
Figure 3.19 Flow Cell ....................................................................................................95 
Figure 3.20 PEGylated CD44 Conjugated Immuno-niosomes Bound to 
Endothelial Cells Under Flow Conditions (400x Magnification) ..............96 
Figure 4.0 IRDye 800CW Bulk Solutions ..................................................................97 
Figure 4.1 IRDye 800CW Reference Samples ............................................................98 
Figure 4.2 4nmol IRDye 800CW Loaded 5% PEGylated Niosomes ..........................99 
Figure 4.3 IRDye 800CW Pipette Standards for Phantom Mouse ............................100 
 
vii 
Figure 4.4 Minimum Detection Limits with Epi-illumination ..................................101 
Figure 4.5 Phantom Mouse Imaged Under Trans-illumination ................................102 
  
viii 
 
 
 
 
PEGylation of Niosomes 
John A. Elliott 
ABSTRACT 
The research presented in this dissertation describes the creation and 
characterization of a novel antibody-vesicle conjugate modified with polyethylene glycol 
(PEG) that possesses enhanced binding to and uptake by inflammation-activated 
endothelial cells with improved storage stability and longer shelf-life and potential 
reduction in immunogenic potential compared to previous designs. 
Targeted drug delivery provides an effective means of delivering therapeutic 
concentrations of a drug to the site or organ of action. The drug is delivered using a 
niosome, a vesicle with an aqueous core and a bilayer membrane composed of non-ionic 
surfactants and cholesterol. Antibodies that recognize specific cell antigens are attached 
to the niosome to complete the targeting molecule, an immuno-niosome (IN). When 
functionalized PEG, a water soluble, biologically inert polymer, is attached to proteins, it 
can protect the protein, increasing its half-life in vivo. The immuno-niosome synthesis 
process is modified to include PEG incorporation into the niosome membrane, a process 
known as PEGylation. 
 Since the vasculature connects the entire body, immuno-niosomes targeted to 
endothelial cells were used. When endothelial cells are activated during disease, stress 
and injury, certain receptors are expressed and upregulated. One such receptor, CD44, is 
upregulated in response to vascular inflammation associated with atherosclerosis. 
ix 
 The research hypothesis is that the addition of polyethylene glycol to the drug 
delivery vesicle (immuno-niosome) using cyanuric chloride linking chemistry will 
improve colloidal stability and binding performance of the PEGylated immuno-niosomes 
to endothelial cell surface receptors expressed during an inflammatory response. The 
research presented in this dissertation provides the following evidence to support this 
hypothesis: 
 Construction and characterization of a modified drug delivery vesicle using 
non-ionic surfactants conjugated with PEG and functionalized with antibodies 
against endothelial cell surface receptors (PEGylated immuno-niosomes) 
improves the colloidal stability over previously designed vesicles. 
 Binding of PEGylated CD44-IN to activated endothelial cells is improved 
over previously designed vesicles. 
 Binding of PEGylated CD44-IN to activated endothelial cells under 
physiological conditions (flow) is demonstrated. 
 Uptake of PEGylated immuno-niosomes by activated or injured endothelial 
cells is demonstrated using confocal microscopy. 
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1. Project Background 
Generally, the most effective and least toxic method of delivery of a therapeutic 
agent is targeting directly to the site of action. Therefore, methods to enhance and 
improve the design of targeted delivery vesicles are increasingly important to avoid the 
deleterious health and drug dilution effects associated with systemic administration. In 
1965 Bangham et al., described the liposome, a self-assembly bilayer phospholipid 
vesicle composed of the cell membrane materials [1-3]. They determined that ions 
encapsulated within the liposomes could diffuse out, similar to the process of particle 
diffusion across a cell or biological membrane. Then, in the 1970's, Gregoriadis 
determined that liposomes could be used to encapsulate proteins, chemotherapeutic drugs 
and other therapeutic agents [4]. Also, in the 1970's, scientists in the cosmetics industry 
developed niosomes, bilayer membrane vesicles composed of non-ionic surfactants [5, 
6]. Since the phospholipids in liposomes are prone to oxidation, niosomes offer better 
stability and shelf-life [7]. Next, with the advent of monoclonal antibody production in 
1975 by Schwaber and Cohen [8], targeting specific sites located on cellular targets 
became feasible. Additionally, the grafting of small molecular weight drug molecules to 
polymer chains, e.g. polyethylene glycol (PEG), was reported to alter the immunological 
properties of the molecule [9] and also reduce renal excretion of the molecule [10, 11]. 
Therefore, to improve the delivery vesicle (niosome) circulation time and provide 
colloidal stability, a biodegradable polymer chain made from polyethylene glycol is 
attached to the niosome surface, a process known as PEGylation. The hydrophilic PEG 
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chain attracts water molecules to the vesicle surface and this hydration inhibits plasma 
protein attachment. Allen et al. and others have shown that PEGylation inhibits 
reticuloendothelial system uptake and provides a site for antibody conjugation that is 
extended away from the vesicle surface [12-15]. During the vesicle production process, 
the functionalized surfactant, PEG, is incorporated into the membrane of the niosome. 
Antibodies targeted to a specific cell surface receptor are conjugated to the terminal end 
of the PEG chain, creating the immuno-niosome [16, 17]. In many disease states, e.g. 
trauma, atherosclerosis, infection and inflammation, specific receptors are expressed on 
the endothelial cell surface [18, 19]. For example, when exposed to cytokines and 
abnormal shear stress, endothelial cells become activated, initiate an inflammatory 
response and express cellular adhesion molecules [20]. Cellular adhesion molecules are 
transmembrane glycoproteins involved in leukocyte recruitment, adhesion and 
transmigration, thus making them potential targets for targeted delivery vesicles [20-23]. 
In particular, CD44, a smooth muscle and endothelial cell surface receptor, is involved in 
inflammation-mediated processes, making it an attractive therapeutic target [24]. CD44 
plays a critical role in inflammation associated with atherosclerosis, the buildup of plaque 
causing hardening of the arteries and progression to heart disease. Blocking antigen 
binding to the activated cell surface CD44 can reduce evidence of inflammation [18]. 
CD44 is also a potential target for solid tumor cells that express the cell surface receptor 
and in some metastatic cancers where elevated levels of soluble CD44 can be found in 
the circulation [25-28]. PEGylated immuno-niosomes are antibody-conjugated targeted 
delivery vesicles made from PEGylated non-ionic surfactants, shown in figure 1.0. 
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Figure 1.0        PEGylated Immuno-niosome 
The research hypothesis is that the addition of polyethylene glycol to the targeted 
delivery vesicle (niosome) using cyanuric chloride linking chemistry will improve the 
colloidal stability and binding performance of the PEGylated immuno-niosomes to 
endothelial cell surface receptors expressed during an inflammatory response. Through 
successful completion of the proposed aims in table 1.0, we provide a stable targeted 
delivery vesicle, the PEGylated immuno-niosome, capable of delivering therapeutic 
agents to specific cellular sites with high specificity. 
Table 1.0        Project Aims 
Aim 1 Construct and characterize a modified vesicle design using non-ionic 
surfactants conjugated with PEG and functionalized with antibodies 
against endothelial cell surface receptors (PEGylated immuno-niosomes). 
Aim 2 Compare and observe binding of PEGylated immuno-niosomes to 
endothelial cell surface inflammatory receptors. 
Aim 3 Develop vesicle designs and techniques for in vivo delivery and imaging 
of the PEGylated immuno-niosomes. 
Cholesterol 
Span 60 
Tween 61 
PEGylated 
Tween61 
Antibody 
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1.1.0 Drug Delivery Introduction 
Design of a targeted drug delivery molecule requires knowledge of biology, 
transport phenomena and pharmacokinetics. Integrating the knowledge derived from 
these fields provides the foundation for modern research and development of most drug 
delivery vesicles and conjugates. Therapeutic agents can be delivered by various routes, 
e.g. oral, ocular, rectal, bronchial, transdermal and systemic. Most of the methods use the 
cardiovascular system for distribution and removal of the agent once it has entered the 
body. The cardiovascular system provides the driving force and infrastructure for the 
distribution of the therapeutic agent throughout the body. Depending on the location of 
the targeted site, distribution is carried out by diffusive and convective forces. When the 
blood is used to transport material through the body, the point of first contact for the 
targeting vesicle is the membrane of the endothelial cell surface.  
1.1.1 Basics of Pharmacokinetics 
Pharmacokinetics is the study of how the body distributes, absorbs, metabolizes, 
and clears a drug after administration while pharmacodynamics describes the biochemical 
and physiological effects of the drug on the body. The basic overview of the process of 
pharmacokinetics is described by the acronym LADME which represents Liberation (L), 
Absorption (A), Distribution (D), Metabolism (M) and Excretion (E). These processes are 
not discreet as some can take place simultaneously. For example, simple compartment 
models can be used to estimate serum levels in order to prevent the occurrence of 
nephrotoxicity. 
Inputs and outputs are the two types of operation described by LADME. 
Liberation and absorption describe input processes where liberation is the release of the 
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drug from its original form and absorption is the movement of the drug from its original 
site of administration into the blood stream. Distribution, metabolism and excretion are 
output operations. Distribution is where the drug diffuses or travels from the intravascular 
space into the tissue. Metabolism is where the drug is broken down or converted into 
forms that are easy to eliminate. Excretion is the elimination of the original compound or 
its metabolites from the body through renal, hepatic or pulmonary routes. 
In the design of drug delivery molecules, the first thing to consider is how the 
drug is to be administered or introduced into the body. Drugs can be delivered by site 
specific methods such as ocular, dermal and bronchial or by broader distribution methods 
of delivery such as oral and intravenous routes. The dermal methods are based on 
adsorption through the skin by a patch that releases the drug over time. The drug is 
absorbed into the blood and distributed, e.g. nicotine and nitroglycerine patches. Oral 
methods of delivery use pills containing simple starch or gelatin binders to control release 
rates in the gastrointestinal tract (GI), with the latter providing a slower release rate in the 
stomach and intestine. A more sophisticated oral delivery method uses an osmotic pump 
across a polymer shell so the drug can be delivered for a longer time. The drawback to 
oral delivery methods is the harsh environment of the GI tract and the low absorption 
rates of some drugs from the GI tract into the blood. The benefit is greater compliance 
since typically the drugs can be taken by the patient without aid from a medical 
professional and without the pain or complications that can be associated with 
intravenous delivery methods. The route chosen for this study is the intravenous route 
since the entire dosage of the administered drug reaches the circulatory system where it is 
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then distributed throughout the body prior to clearance by hepatic, renal and proteolytic 
enzyme routes. 
1.1.2 Compartment Models 
  When the drug enters the blood stream, the central volume (Vc) describes the 
volume of blood in the vessels. This includes any tissues that are highly perfused with 
blood and where the drug may distribute. The peripheral volume (Vp) describes blood in 
the tissues outside of the central volume. Together Vc and Vp make up the volume of 
distribution (Vd), which is the total fluid volume the drug is dissolved in [29]. Together, 
the terms Vc, Vp and Vd are used to approximate the amount of drug in the body, peak 
serum levels and the clearance of the drug from the body. The clearance (Cl) of the drug 
from the blood is another important term that describes the behavior of the drug in vivo. 
The rate of drug clearance is described by a constant called the elimination coefficient 
(kel), which describes the fraction of drug eliminated per unit time. The constant is 
patient-specific because it is based on the capacity and functionality of specific organs 
that can be impacted by disease and the administered drug treatment. The clearance 
calculation is shown in equation 1.0. 
 Cl = kel*Vd  Equation 1.0 
The simplest way of characterizing a drug in the body is to use first order kinetics 
and a single compartment model. In reality, first order kinetics holds up for most drugs 
while the single compartment model works if serum samples are collected after the drug 
moves into the tissues. The one compartment model is used for drugs that perfuse rapidly 
while the two compartment model takes into account the distribution phase. When 
graphing the two models, the one compartment model will yield a straight line on a 
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logarithmic y axis. The two compartment model yields a biphasic line on the same graph, 
indicating the distribution phase. Some drugs, when administered by intravenous infusion 
over a time course, will follow a three compartment model consisting of distribution, 
elimination and tissue release. In encapsulated drug delivery design, the tissue release of 
the drug can be coordinated with the time release from the vesicles. This is a beneficial 
attribute of encapsulated delivery methods since drug plasma concentrations are 
maintained for long time periods without the initial high drug plasma concentrations 
associated with non-encapsulated delivery techniques. 
The body can be modeled as a set of compartments connected in parallel and/or 
series with the blood plasma as the conduit between the organs, as shown in figure 1.1.  
 
Figure 1.1        Simple Compartmental Model 
With rate constants representing the coefficients for drugs entering and leaving a 
particular compartment (k12, k21), the liver and kidneys act as a sink (k20) where the 
drug is metabolized and/or extracted from the plasma through hepatic and renal 
clearance. This multiple compartment model is still incomplete because there are 
intercellular and extracellular space interactions and intracellular compartment 
interactions within each organ. More advanced modeling is being investigated in order to 
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incorporate physiological data from experiments [30]. Another method used to 
characterize the drug in the body is to take into account the complex design of the 
vascular bed and to implement fractal analysis [31, 32]. 
1.2.0 Introduction to the Cardiovascular System 
The major components of the cardiovascular system are the heart, vessels and 
blood circulated throughout the body. The entire vascular system is lined with endothelial 
cells providing a blood contact surface. Therefore, the cells play an active role in the 
cardiovascular system. The system is considered a closed loop because it is a sealed 
system where all the fluid is maintained and circulated within an enclosed body. It should 
be noted that a water cycle exists where fluids are absorbed through the GI tract, 
replenishing the large water content that leaves the system through renal excretion, sweat 
and respiratory function. The system provides transport of vital nutrients and fluids to all 
the organs in the human body making it an attractive avenue for drug delivery schemes. 
Because the operation of the cardiovascular system is essential for life, it is also a target 
for therapeutic intervention and treatment.  
1.2.1 Blood  
 The fundamental role of blood is maintenance and homeostasis. It is a fluid 
composed of a multitude of components ranging from cells to proteins and trace minerals. 
Blood density is very close to pure water as shown in table 1.1, 1050 kg/m
3
 compared to 
1000 kg/m
3
.  
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Table 1.1        Physical Properties of Blood 
Property Values 
Density 1050 ± 7 [kg/m
3
] @ 37°C 
Viscosity at shear rate 3.26 ± 0.43 [mPa*s] at shear rate of 100 [1/s] 
4.37 ± 0.60 [mPa*s] at shear rate of 50 [1/s] 
5.46 ± 0.84 [mPa*s]  at shear rate of 1 [1/s] 
pH 7.4 ± 0.05 [H
+
] 
Osmotic colloidal pressure 284  [mm H2O] 
 
The cellular component of blood can be divided into three main groups with 
subtypes as shown in table 1.2. The three main cell types are erythrocytes or red blood 
cells (RBC), leukocytes or white blood cells (WBC) and thrombocytes or platelets. 
Whole blood contains all the cellular and fluid components. Plasma contains the whole 
blood soluble factors only, with the cells separated out by centrifugation. Once whole 
blood has clotted, the remaining liquid component is serum. It is similar to plasma except 
that it lacks the clotting factors. The plasma makes up approximately 55% of the blood by 
volume and carries nutrients, proteins and trace minerals and acts as a pH buffer. The 
plasma is composed primarily of water and contains numerous low molecular weight 
organic and inorganic materials and about 7% protein, e.g. albumin, fibrinogen and four 
major groups of globulins.  
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Table 1.2        Blood Cell Types 
Type Sub Type Function 
Erythrocytes Red Blood Cells Carry oxygen to tissues in the body. 
Leukocytes Neutrophil Bacterial and fungal targeting. 
Eosinophil Parasite targeting and allergy mechanisms. 
Basophil Contains histamine and heparin, involved in 
specific inflammatory and allergic processes. 
Lymphocytes 
(Natural Killer cell) 
(B cell and T cell) 
NK cells remove tumors and viral-infected 
cells by cytokine induced apoptosis. 
B and T cells are frontline agents in the 
adaptive immune system. 
Monocyte Replenish macrophages and fight infection. 
Thrombocytes Platelets Regulation in blood clotting and inflammation. 
 
A Newtonian fluid is described as a fluid that is non-compressible. The viscosity 
is a function of temperature and pressure only and is described by Newton’s Law of 
Viscosity where the shear stress  is a function of the velocity profile  multiplied by 
a constant of proportionality  as shown in equation 1.1. 
       Equation 1.1 
Blood can be approximated as a Newtonian fluid when circulating in large vessels. 
However, when the vessel radius approaches that of capillaries, the red blood cells and 
plasma separate into two phases and blood can no longer be considered a Newtonian 
fluid. The blood flow is described as smooth (laminar) or turbulent depending on the 
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fluid path. In smooth flow, there are no disruptions in the axial direction and the cross 
sectional velocity patterns are described as plug or parabolic. In plug flow the cross 
sectional velocity is constant, creating high shear rates that act on the vessel wall. In plug 
flow it is assumed there is no boundary layer at the wall surface. When the velocity 
profile is parabolic, the fluid in the center of the vessel has the maximum velocity and the 
fluid at the wall has the slowest velocity. The parabolic profile creates conditions that can 
impede particles from reaching the vessel wall. This condition was first described by 
Segre and Silberberg in 1962. The phenomenon causes particles that are near the wall to 
migrate toward the axial position and particles that are in the axial position migrate 
toward the wall. When blood is initially ejected from the heart, it travels through the large 
arteries in a plug profile which becomes parabolic as the cycle continues. This effect is 
less pronounced as the blood travels further away from the heart into smaller vessels (not 
including the capillaries). Turbulent flow occurs at bifurcations and in pathological 
conditions such as atherosclerosis where hardening of the arteries and plaque formation 
disrupt the normal blood flow. Fluid flow can be described by the velocity profile, 
pressure drop and the wall shear stress where the difference in pressure is the driving 
force causing fluid flow. Blood is circulated based on the principle that a fluid flows from 
an area of higher pressure to lower pressure, analogous to heat flow. The ventricles in the 
heart contract and force the blood out, creating the driving force, so the blood will move 
from an area of higher to lower pressure. 
1.2.2 Heart 
 The human heart is a four chamber pump driven by and composed of myocardial 
muscle tissue and it provides the driving force for blood circulation through the entire 
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system. The myocardial muscle tissue is surrounded by the pericardium, a tough inelastic 
multilayered tissue. The inner walls of the myocardium are lined with endocardial tissue 
composed of endothelial cells covering trabeculae. The left and right coronary arteries are 
positioned on the outer surface of the muscle tissue and feed blood to the myocardial 
muscle. To control the direction of blood flow, there are four valves, two valves that are 
actuated by papillary muscles and two cuspid valves that are passive and are operated by 
the pressure differential across the valve. 
1.2.3  Circulation 
The blood is returned from the body to the right atrium through two veins, the 
superior and inferior vena cava. Blood flows from the right atrium through a tricuspid 
valve into the right ventricle and is pumped through the right and left pulmonary arteries 
to the lungs through a semilunar valve. In the lungs, a gas exchange occurs between the 
air in the alveolar sacs and the lung capillaries. After this exchange process, the blood is 
now ready to deliver oxygen to the various tissues in the body. The oxygenated blood is 
returned to the heart through the right and left pulmonary veins to the left atrium. The 
blood traverses across the mitral valve into the left ventricle where it is ejected across the 
aortic valve into the aortic arch and the descending aorta. From the major arteries, the 
vessels continue to branch out into smaller arteries, transitioning from the arterioles to the 
smallest group of vessels called capillaries. The arterioles are responsible for the 
peripheral resistance in the cardiovascular system; this resistance is directly related to 
arterial pressure from the restriction of blood flowing from the arteries through the 
arterioles. The capillaries contain the largest total cross-sectional surface area in the body 
and are present in every tissue. They contain a single layer of endothelial cells 
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surrounded by basal lamina. Capillaries are the pathway for the delivery and exchange of 
oxygen, carbon dioxide and critical nutrients to the surrounding tissues in the body, 
making them a focus for targeted drug delivery techniques. The fluid that carries nutrients 
from the capillaries is collected in the lymphatic ducts. The lymphatic system is 
responsible for removing fluids from the tissue interstitial spaces around the body and 
returning those fluids to the blood stream. The blood is returned to the heart by a 
complementary set of vessels called veins which completes the closed loop of the 
cardiovascular system. 
1.3.0  Cell Introduction 
Cells are contained within the tissues of all living creatures. Cells can be divided 
into two distinct types, eukaryotes, cells with a nucleus and well-developed intracellular 
organelles and prokaryotes, cells without a discrete nuclear membrane. The basic 
structure of a cell consists of a fluid core surrounded by a bilayer lipid membrane. The 
internal space of eukaryotic cells, the cytoplasm, is a fluid core with membrane-bound 
organelles and a nucleus. The cytoplasm contains many small and large molecules and 
the cell transports material into the cytoplasm and between organelles using small 
membrane-bound vesicles. The nucleus contains the information the cell needs to 
function and replicate. Energy for cellular processes is generated in the mitochondrion. 
Mitochondria produce adenosine triphosphate (ATP) that is used as an activated energy 
carrier in biosynthesis reactions and is also responsible for cellular functions such as the 
cell cycle and growth. The nucleus is surrounded by a double layer membrane with pores 
that allow the transfer of material. Ribosomes within the cytosol are sites of protein 
synthesis where messenger RNA transcribed in the nucleus is translated into protein on 
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the ribosomes. An additional multifunctional cytoplasmic organelle is the endoplasmic 
reticulum (ER). The rough endoplasmic reticulum (RER) is coated with ribosomes. The 
formed proteins can be further modified on the surface of the RER. There is another part 
of the ER called the smooth endoplasmic reticulum (SER) that is responsible for 
specialized functions like lipid and steroid production. The proteins formed at the free 
ribosomes, RER and SER are transported to an organelle called the golgi apparatus. The 
golgi apparatus functions primarily as a cellular post office where the material is sorted, 
packaged and sent to the proper destination within the cell. Lysosomes import and 
recycle materials using digestive enzymes. Lysosomes have an internal pH of 4.8. 
Materials transported into the cell by endocytotic vacuoles are typically shuttled to an 
acidic vacuole called an endosome. The endosome sorts recyclable materials to the 
plasma membrane or delivers them to the lysosome. This transport and recycling feature 
is important in developing drug delivery strategies because therapeutic agents can be 
degraded by the acidic conditions. 
1.3.1 Endothelial Cells 
The vasculature is lined with a single layer of endothelial cells providing the 
blood contact surface in the heart, arteries, veins and lymphatic system. The endothelial 
cell is a subtype of the epithelium which lines human body cavities and tissue structures. 
One feature of the endothelial cell type is that it expresses the E-cadherin adhesion 
molecule on its surface. There are differences between arterial and venous endothelial 
cells and it has been shown that the genetic coding determines the cell phenotype [33]. In 
fact, different phenotypes are seen in the five different types of endothelial cells found in 
the heart (endocardial, coronary, arterial, capillary and lymphatic) [34]. There are 
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organizational/orientation differences between the endothelial cells (arterial versus 
ventricular) covering the aortic valve. The cells are aligned in different patterns to 
compensate for the physiological stresses they encounter. A transmission electron 
microscope image of an endothelial cell on an aortic valve is shown in figure 1.2 
 
Figure 1.2        Endothelial Cell on Aortic Valve (arterial) 
Variations in permeability of the endothelial cell layer in large arteries and 
capillaries are caused by the underlying structural components of the different vessels. 
The large arteries transport blood and the capillaries function to deliver vital molecules 
and fluids to the tissue intracellular spaces. The main arteries allow passage of oxygen 
and small molecules from the blood through the endothelial cells into the arterial 
substructure to maintain the smooth muscle cells. The lymphatic system is a low flow 
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system that maintains intracellular fluids and has the potential to become a target for 
developing anti-inflammatory treatments [35]. There are also interactions between tumor 
cells and the lymphatic system making it a focus for anti-cancer treatment strategies.  
1.3.2  Endothelial Cell Mass Transport 
For intravenous targeted drug delivery, the endothelial cell surface is the first 
point of contact, whether the surface of the cell is the intended site of therapy, the drug is 
to be transported into the cell, or the drug needs to cross the endothelial cell barrier to 
reach the underlying tissues. The selection of the cell surface receptor is matched to the 
delivery vesicle using knowledge of the receptor’s temporal expression and binding 
affinity. The targeting strategy dictates the size and composition of the delivery vesicle to 
provide the behavior required in the area of interest since it may need to overcome 
convective forces due to blood flow momentum in great vessels or shear forces in smaller 
vessels. Depending on the application of the therapeutic agent, the mass transport 
interactions with the endothelium can be characterized as: a reactive surface, a reactive 
wall or a semi-permeable membrane shown in table 1.3 [36].  
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Table 1.3        Endothelial Transport Equations [36] 
Process Equation Important Conditions 
Reactive Surface Cs/Cb =1/(1+ Dar /Sh), Equation 1.2 Dar  << Sh 
Dar  >> Sh 
Semi-Permeable  
Membrane 
Cs/Cb =1/(1+ Dac /Sh), Equation 1.3 Dac >> Sh 
Reactive Wall Ps,A/Pb,A=1-Daw/Sh, Equation 1.4 Dar  << Sh 
Dar  ≈ Sh 
 
As a reactive surface, Michaelis-Menten kinetics (MMK) are used to model the 
interactions at the surface. MMK describe biological reactions involving enzymes and 
assume the reaction is irreversible and that the product does not bind or occupy the 
enzyme. The Damkohler number (Da) is a ratio relating the reaction rate to the mass 
transport rate and the Sherwood number (Sh) is used to relate the convective and 
diffusive forces. When the surface concentration is equal to the concentration found in 
the blood stream, reactive surface equation 1.2 is reaction limited. When the Damkohler 
number is much greater than the Sherwood number (Dar  >> Sh), the reactants are present 
at the wall in concentrations high enough or in excess for the reaction. The diffusive and 
convective forces that bring the reactants from the blood stream to the cell wall do not 
influence the reaction.  
When the endothelium is described as a semi-permeable membrane for small 
molecules, equation 1.3 shows that when the Damkohler number is much larger than the 
Sherwood number, the system is transport limited or fluid-phase limited. In larger vessels 
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this means it will be more difficult for large molecules and particles to move to the 
endothelial surface. In contrast, smooth flow patterns will allow smaller particles to 
diffuse to the endothelial surface more quickly. This illustrates how a vesicle that is 
attached to the endothelial surface at a site of therapeutic interest can take advantage of 
this process. In the capillary vessels, there is a phenomenon called shear thinning that 
takes place. This occurs because the diameter of the red blood cell is similar to that of the 
vessel. The red blood cells separate from the plasma and travel down the center of the 
vessel and the plasma is pushed toward the wall surface creating a non-Newtonian liquid 
with two distinct phases. The effect of the plasma being located near the wall creates a 
fluid phase that the delivery vesicle will occupy when in close proximity to the binding 
site on the vessel wall.  
At the reactive wall, there is consumption or a sink on the mass balance. The act 
of oxygen transport from the blood stream to the vessel wall is an important process that 
is required to maintain homeostasis of the vessel. Equation 1.4 shows that when the 
Damkohler number is much smaller than the Sherwood number, the reaction is limited by 
the reaction rates associated with the wall, and transport phenomena does not play an 
important role. As the Damkohler and Sherwood numbers approach one another, the 
reaction is limited by transport of the reactant to the wall, and convective and diffusive 
forces become important. This has been used to explain endothelial dysfunction in 
coronary arteries leading to a leaky vascular wall and allowing the influx of low density 
lipoproteins, a primary step in atherosclerotic plaque formation.  
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1.3.3 Endocytosis   
Endocytosis is the uptake of nutrients, fluids, large and small molecules and 
particles in cells. There are two main pathways for endocytosis, phagocytosis and 
pinocytosis. Phagocytosis is described as a process where the cell engulfs large particles 
(>250nm) by folding its membrane around the particle. Pinocytosis is a process where a 
cell uptakes liquids and small molecules (<150nm) inside pits that are formed in the cell 
membrane and that pinch off forming vacuoles that carry the contents to various 
intracellular locations [37]. Phagocytosis is a process that specialized cells in the immune 
system use to remove pathogens and debris and is the process that macrophages use to 
complete housekeeping duties throughout the body. Phagocytosis is a major pathway for 
specialized cells like macrophages, but is rare in endothelial cells in situ. However, Muro 
et al. reported that endothelial cells can internalize large particles up to 5 um in size [22]. 
Considering the rarity of phagocytosis in endothelial cells in vivo, it has not been a focus 
of most targeted delivery schemes. However, since macrophage activity is a process 
associated with tissue injury and inflammation, the macrophage is an attractive target for 
therapeutic treatment [38]. Pinocytosis and receptor-mediated pathways are also used to 
deliver a payload to the site of interest. Pinocytosis is a non-specific uptake of 
extracellular fluids and small molecules and can be used to deliver a reservoir to the cell 
surface. The reservoir contents are eluted into the extracellular fluid and diffusion 
becomes the driving force for delivery. Uptake pathways are described by four main 
groups: macropinocytosis, clathrin-mediated endocytosis (CME), caveolae-mediated 
endocytosis (CavME), and clathrin-caveolae-independent-internalization [39, 40]. CME 
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and CavME both provide non-specific pathways for the uptake of adsorbed molecules 
through invaginations found on the cell membrane.  
The caveolae are small 60-80 nm plasma membrane invaginations used for 
endocytosis, exocytosis, transcytosis and the internal transport of macromolecules [41]. 
They do not have a large volume and are typically lined with receptors such as gp60, an 
albumin specific receptor. The CavME pathway has been well studied and provides a 
promising route for delivery to the endosome, caveosome and the cell nucleus [42]. The 
selection of these different delivery routes is based on interactions of the surface lipid 
rafts, integrins and proteins. Caveolae are involved in the transcytotic and exocytotic 
processes which are directed by secondary protein interactions. 
1.4.0 Cell Surface Receptors 
Targeted drug delivery can be used to target cell types based on size, charge and 
binding schemes using cell surface receptors and receptors found within the pits formed 
during pinocytosis. Cells continually express protein and carbohydrate receptors for 
ligands both externally on their membrane surface and internally for a variety of 
functions. The receptors that are expressed vary between cell types and some of them 
may only be up-regulated during certain stages of disease or injury, such as receptors for 
inflammation. Cell surface receptors may be either integral or peripherally attached to the 
membrane. Peripheral receptors are composed of proteins that are temporarily attached to 
the cell membrane and function in a regulatory manner. They are not as common as the 
integral types. Peripheral and integral membrane receptors are required cellular 
homeostasis. The functions of the receptors vary from adhesion, signaling and 
communication to the extracellular matrix and other cells, as well as triggering cellular 
21 
processes such as apoptosis, endocytosis and mitosis. Transmembrane receptors are 
integral in nature and their protein structures penetrate through the membrane into the 
cytoplasm for intracellular signaling. The integral membrane proteins are typically made 
from alpha helices and beta sheets. Integral proteins can be grouped into six categories 
based on how the structure interacts with the lipid membrane of the cell (table 1.4, [14]). 
Table 1.4        Integral Membrane Protein Types 
Type Description 
I One helix structure with terminal amino group on the outside and carboxyl 
group on the inside of the cell membrane. 
II One helix structure with terminal carboxyl group on the outside and amino 
group on the inside of the cell membrane. 
III Multiple helix structure penetrating the cell membrane using a single 
polypeptide. 
IV Multiple helix structure formed by different polypeptides creating a channel 
through the membrane. 
V Proteins that are attached to the lipid membrane by covalently linking to 
lipid molecules without passing through the membrane. 
VI Single polypeptide structure that passes through the cell membrane and has 
a type V lipid anchor. 
 
The delivery vesicle encounters the cell membrane surface receptor and this is the 
first target for most delivery schemes. A secondary interaction with peripheral receptors 
could provide additional targeting benefits. Inflammatory receptors are cell surface 
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receptors that are up-regulated by the cell during conditions of disease, injury and 
infection. Inflammatory receptors include the cellular adhesion molecules (CAMs) which 
can be expressed on the cell surface, intracellularly or within the extracellular matrices of 
tissues. The CAM family can be grouped into five groups based on protein type. These 
are: immunoglobulins, selectins, addressins, integrins and cadherins. Of these five, three 
have been used for targeting the arterial endothelium. The CAM groups, the 
immunoglobulins, selectins and cadherins, provide potential binding sites for therapeutic 
particle delivery (table 1.5). 
Table 1.5         Common Cell Adhesion Molecules (CAMs) 
Type Name Function 
IgG ICAM-1 InterCellular Adhesion Molecule 1 is expressed by leukocytes 
and endothelial cells and is responsible for leukocyte 
extravasation into tissues from the blood stream during an 
inflammatory response [43]. 
IgG CD44 Is involved in cell to cell interactions and is expressed by 
endothelial cells during inflammation, atherosclerosis, 
rheumatoid arthritis and cancer [44-46]. 
IgG VCAM-1 Vascular Cell Adhesion Molecule-1 is expressed by activated 
endothelium during inflammation. It is expressed by large and 
small vessels and is associated with atherosclerosis. Some 
melanomas use it to attach to the endothelial cell surface [47-
49]. 
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Table 1.5 (Continued) 
IgG PECAM Platelet Endothelial Cell Adhesion Molecule is found on 
endothelial cells, platelets, macrophages, neutrophils and 
Kupffer cells. It plays an important signaling role in 
thrombosis and between macrophage cells and dying 
neutrophils [50, 51]. 
Selectin E-selectin A low affinity cell adhesion molecule expressed only by 
endothelial cells during inflammation. It allows leukocytes 
to bind in a reversible manner known as leukocyte rolling 
[52, 53]. 
Selectin P-selectin A cell adhesion molecule similar to E-selectin but 
expressed very quickly as it is stored in endothelial cells 
preformed and does not need to be synthesized [54, 55]. 
Selectin L-selectin A cell adhesion molecule that is associated with lymphatic 
endothelial cells. It functions like E-selectin and P-selectin 
and is used for leukocyte recruitment [56-58]. 
Cadherin VE-cadherin VE-cadherin is an intracellular adhesion molecule that is 
responsible for the integrity of the junctions between 
endothelial cells [59, 60]. 
Cadherin T-cadherin  
H-cadherin 
T-cadherin is highly expressed in the heart and aorta and is 
upregulated in atherosclerotic lesions and tumor 
penetrating blood vessels [61-63]. H-cadherin is associated 
with cancer and tumor development [64-67]. 
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1.4.1  Proteins 
Proteins are responsible for most of the functions that take place in a cell. They 
are the most complex molecules found with regard to their structure and function. They 
are comprised of a combination of amino acids that have side chains that give them 
distinct chemical functions. Polypeptides are formed when the amino acid molecules are 
linked together by a covalent peptide bond forming linear polymers with functional side 
chains. Some proteins have a negative or positive charge, some are uncharged or polar, 
and some are hydrophilic. The noncovalent interactions between the side chains cause the 
linear polypeptide sequence to take shape. Hydrogen bonds, ionic bonds and van der 
Waals attractions are responsible for secondary structure of the molecule. The peptides 
will shift to a conformation with the lowest energy level. This is determined by 
temperature, pH and the solvent. The two major structures that are commonly formed are 
the alpha helix and beta pleated sheet. Βeta pleated sheet structures resemble ribbons with 
polypeptide chains running in the same direction in a parallel structure or an alternating 
direction forming an anti-parallel sheet structure. Proteins form alpha helix structures to 
cross the cell membrane. 
1.4.2 Antibodies  
The immunoglobulin superfamily (IgSF) is a large group of cell surface and 
soluble proteins made from amino acids that contain an immunoglobulin (Ig) domain. 
The Ig domains contain two layers of β pleated sheets and three to four anti-parallel 
polypeptide chains. The Ig structure anti-parallel beta sheets are characterized by the 
conserved disulfide bond that links the two sheets together. All the proteins with these 
immunoglobulin domains belong to the IgSF (the structures are involved with cell 
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recognition, binding, adhesion and receptors for antigens and cytokines). Antibodies 
belong to this superfamily and bind to their specific antigens with high affinity and 
selectivity [68]. These antibodies are used to target inflammatory receptors in the 
described studies. There are five different classes or isotypes of human antibodies shown 
in table 1.6. They contain polypeptide structures grouped into regions called chains with 
constant regions that are conserved and variable regions that form the binding sites for 
specific antigens. All five classes have the same fundamental four chain structure made 
from a pair of identical heavy chains and a pair of identical light chains held together as a 
tetramer with disulfide bonds. In 1959 Porter, showed that the antibody could be cleaved 
using the proteolytic enzyme papain, into three major structures that compose 90% of the 
original molecule (figure 1.3). He noted that two of the structures retained the ability to 
bind with antigen and had nearly identical chemical properties. He also noted the third 
fragment had very different chemical properties and did not bind with antigen. This was 
the first clue that immunoglobulins had a “Y” structure composed of the three groups he 
found after the papain digest. The two identical structures are called fragment antigen 
binding arms (Fab) and the third region is called fragment crystalline (Fc) [69] (figure 
1.3). The five classes of antibodies each have distinct heavy chains which are used for 
classification, as listed in table 1.6.  
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Table 1.6        Human Immunoglobulin Types 
Type Heavy Chain Description 
IgA α Dimer that is found in mucous and breast milk provides 
protection from pathogen colonization [70]. Can survive 
conditions in the gastrointestinal tract [71]. 
IgD δ Monomer that is located on the surface of B cells and 
acts as an antigen receptor [72]. 
IgE ε Monomer that binds its Fc region to leukocytes and binds 
to allergens to trigger the release of histamine. [73] It 
also initiates an immune response to parasitic worms 
[74], [75]. 
IgG γ Monomer and the immunoglobulin that is responsible for 
the secondary immune response. Comprises 75% of the 
immunoglobulin found in serum[76]. 
IgM μ Pentamer immunoglobulin that is the largest and first 
found in the blood or in monomer form on the cell 
membrane [77]. 
 
1.4.2.1     Immunoglobulin G 
The IgG family of antibodies comprises 75% of the antibodies found in human 
plasma. The four major classes of human IgG are IgG(1), IgG(2), IgG(3) and IgG(4) with 
IgG(1) being the most abundant of the four classes [78]. Immunoglobulin contains 
glycoproteins produced by specialized lymphocyte cells. These specialized lymphocytes 
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originate from hematopoietic stem cells and terminally differentiate into plasma cells and 
memory B cells. The genetic code that is developed during this maturation process is 
based on four genes, the variable (V), diversity (D), joining (J) and constant (C) gene. 
The cell line that produces IgG has the following lineage. The stem cells differentiate into 
pro-B cells pre-B cells, and then immature B cells. At this stage, the cells are located in 
the bone marrow and they are antigen independent. The cells then migrate into the spleen, 
tonsils and other peripheral lymphoid tissues and some become mature B cells, and 
collect in areas that are rich in helper T cells. These specialized areas in the tissues are 
known as germinal centers. When the mature B cell is activated by a helper T cell, it 
divides and differentiates into a centeroblast by a process called somatic hypermutation. 
After somatic hypermutation, the precursor cell is called a centrocyte prior to becoming a 
plasma cell or a memory B cell. During B cell maturation, the genetic code that is 
responsible for the makeup of the variable binding region is determined through a process 
called VDJ recombination. The variable chain has three domains that are encoded by the 
V, D and J genes.  During the VDJ recombination process, base pair changes are 
introduced for both heavy and light chain variable regions. In this way, the immune 
system is able to make a diverse group of antibodies that are able to recognize multiple 
antigen types. 
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Figure 1.3        Immunoglobulin G (IgG) 
1.4.2.2     Monoclonal Antibodies 
The advent of methods of monoclonal antibody production in the mid 1970’s was 
made possible by Paul Erlich’s “magic bullet” concept.  The technique was first 
described in 1973 by Schwaber and Cohen and they reported being able to produce 
human-mouse antibodies by fusing mouse myeloma and human peripheral lymphocytes, 
creating hybridomas [8, 79]. There has been controversy over this paper and Kohler and 
Milstein in 1975 reported production of monoclonal antibodies by fusing mouse 
melanoma cells with spleen cells from an immunized mouse [80]. They were recognized 
as the first group to produce antibodies using the hybridoma technique. 
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1.4.3 CD44 Receptor 
CD44, shown in figure 1.4, is a cell surface receptor that remains expressed on the 
cell surface or that can be shed or released into circulation by enzymatic cleavage, 
becoming soluble CD44 [27]. CD44 is involved in many functions including cell to cell 
interactions with leukocytes and endothelial cells and remodeling of the extracellular 
matrix during cell to substrate interactions in embryonic development [81]. There are 
typically two forms of CD44, the standard and the variant form. A single gene with 20 
exons encodes CD44, and the standard form is the most prevalent, consisting of exons 1-
5, 16-18 and 20. Exons 6-15 are called variant exons v1-v10. The variant exons are 
spliced in different combinations in the stem portion of the receptor [82].  
 
Figure 1.4        CD44 Genomic Sequence and Receptor Structure [82, 83] 
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CD44 is a transmembrane glycoprotein in the cellular adhesion molecule family 
and is the major receptor for hyaluronan [84]. CD44 is expressed by many cell types 
throughout the body including the keratinocytes [85] and red blood cells [86]. The CD44 
receptor, expressed by both endothelial and smooth muscle cells is involved in 
inflammation-mediated processes, making it an attractive therapeutic target [24]. It has 
been shown to play a critical role in inflammation associated with atherosclerosis, and 
blocking binding to the CD44 receptor can reduce evidence of inflammation [18]. CD44 
is also expressed on various cancer cell surfaces and has been implicated as a marker for 
cancer when found in high levels in its soluble form in the circulation [25, 28, 44]. 
1.4.4 Intercellular Adhesion Molecule (ICAM) 
Intercellular adhesion molecule (ICAM) is found in three forms (ICAM-1, ICAM-
2 and ICAM-3) and is part of the immunoglobulin superfamily. It is expressed by 
cytokine-activated vascular endothelial cells, macrophages, fibroblasts, smooth muscle 
cells, keratinocytes and leukocytes. The normal function of ICAM is to provide binding 
between endothelial cells and leukocytes during injury and infection by binding to 
leukocyte function association antigen (LFA) or macrophage-1 antigen (Mac-1). ICAM is 
also a receptor for human rhinoviruses and malaria-infected erythrocytes [87]. ICAM-1, -
2 and -3 are type I transmembrane glycoproteins that are all involved in the LFA immune 
response [88].  
ICAM-1 was first discovered in 1986 [89] followed by the discovery of ICAM-2 
in 1989 [90] and finally ICAM-3 in 1992. ICAM-3 is expressed by lymphoid but not 
endothelial cells [91]. The ICAM-1 and ICAM-2 receptors are normally expressed in low 
concentrations on endothelial cells but are highly upregulated after exposure to the pro-
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inflammatory cytokines, tumor necrosis factor alpha (TNF-α) and interleukin-1 (IL-1), 
making them an attractive binding target for drug therapy. ICAM-1 is encoded by human 
chromosome 19. It has a total of seven domains. Five are in the extracellular space with 
D1 and D3 as active binding sites [92] as shown in figure 1.5. 
 
Figure 1.5        ICAM-1 
1.4.5  Vascular Cellular Adhesion Molecule (VCAM)  
Vascular cellular adhesion molecule (VCAM-1) is a member of the 
immunoglobulin superfamily and is encoded by human chromosome 1. It is expressed 
only by cytokine-activated endothelial cells in large and small vessels, and like ICAM-1 
it binds leukocytes via the leukocyte function association antigen (LFA) [93]. It differs 
from CD44 and ICAM since it has two binding sites in domains 1 and 4 for very late 
antigen (VLA-4) expressed by T and B lymphocytes, monocytes, basophils and 
eosinophils [94] (figure 1.6). Metastatic melanoma cells bind to VCAM expressed on 
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endothelial cells [95]. It has also been shown that the adhesion molecule facilitates 
migration of leukocytes into the lymph nodes [96]. VCAM is upregulated at sites where 
arterial atherosclerotic plaques develop during the progression of this chronic disease. 
VCAM expression is associated with the recruitment of monocytes and macrophages that 
infiltrate arterial tissue and venous grafts, making it an attractive drug delivery target [97, 
98]. 
 
Figure 1.6        VCAM-1 
1.5.0 Cytokines and Inflammation 
Cytokines are extracellular signaling molecules that are required for cell-cell 
communication. They share several properties, which include: secreted briefly and are 
self limited, can be produced by multiple cell types, act on different cells types, action 
can be redundant and can influence the production and action of other cytokines. 
Cytokine chemical signaling can be grouped into autocrine, paracrine and endocrine 
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action. Autocrines are chemical agents that influence or act on the cell from which it was 
secreted. Paracrine action is where a cytokine acts on a different type of cell than the one 
that secreted it in the same area of a tissue. Endocrine action is where a cytokine secreted 
in the blood stream is distributed into tissues by blood and extracellular fluids. Cytokines 
are classified into three major groups that describe their function: interleukins, 
lymphokines and chemokines. Interleukins were first classified as molecules that were 
produced by a population of blood leukocytes and that interacted with other leukocyte 
populations [99]. However they are produced by other cell types and many newly 
discovered cytokines are designated with the interleukin nomenclature to prevent naming 
ambiguity [100]. Lymphokines are a class of cytokines that are produced by activated T-
lymphocytes in response to specific immunity [101]. Chemokines are pro-inflammatory 
cytokines released by cells and are used to signal or attract other cells to a site of injury or 
infection. The name is derived from chemotactic cytokines. Two specific cytokines, 
tumor necrosis factor alpha and interleukin-1, are further described in sections 1.5.1 and 
1.5.2, because of their interactions in vascular tissues and one is used later in experiments 
to invoke a desired reaction from cultured endothelial cells. 
1.5.1 Tumor Necrosis Factor Alpha 
Since inflammation is a cellular response to injury, stress or infection, cells will 
upregulate specific receptors in response to those stresses. The inflammatory response is 
defined by the recruitment of leukocytes to the affected tissue and a shift in the fluid 
exchange balance through the arterial wall [102, 103].  
Tumor necrosis factor alpha (TNF-α) and interleukin-1 (IL-1) are both mediators 
of inflammation. The process of inflammation was elucidated by Menkin in 1959 when 
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he described a mediator he called necrosin as being endogenous in nature. In 1975, the 
mediator TNF-α was defined by Carswell and Old. It behaved like necrosin, previously 
described by Menkin [104]. TNF-α is highly conserved among species [105] and its 
function is concentration dependent. At low concentrations it is a pro-inflammatory 
cytokine and causes the upregulation of endothelial cell receptors and activation and 
upregulation of macrophages and leukocytes. At higher concentrations it causes cell 
apoptosis and has anti-tumorogenic properties. [106] 
1.5.2 Interleukin 1  
Interleukin 1 (IL-1) was one of the first cytokines described by scientists, like 
Menkin and Beeson in the 1940s as an endogenous pyrogen because of its ability to 
induce fever when purified samples were administered to normal animals [107]. The 
entire interleukin group contains over 30 members and IL-1 is a family of pro-
inflammatory molecules containing 11 members, all encoded by separate genes [100]. 
Both IL-1 alpha (IL-1α) and beta (IL-1β), are pro-inflammatory molecules in their mature 
or active forms. The molecules are encoded by a 7 exon gene on chromosome 2 of the 
human genome and are produced as precursor peptides. The precursors are proteolytically 
cleaved to become the mature or active forms. 
1.6.0 Cardiovascular Disease 
Cardiovascular disease is the number one killer of adults in the United States and 
according to the American Heart Association, 864,480 Americans died in 2005 from 
some form of cardiovascular disease. Cancer was responsible for 559,312 deaths and 
accidents for 117,809 deaths. Coronary heart disease caused one in five deaths in the 
United States in 2004 [108]. Coronary heart disease is caused by atherosclerosis, a 
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pathological disease causing narrowing of the coronary arteries due to the buildup of 
oxidized lipids, macrophages and smooth muscle cells in the vessel wall. This process is 
characterized by an inflammatory response perpetuated by endothelial dysfunction [109] 
followed by the accumulation of lipids [110], recruitment of leukocytes [111], and 
activation of smooth muscle cells [112] which eventually form mature plaques. This 
pathological process occurs over the course of several decades and can be described in 
six stages. The first stage has been shown to start in as early as the first decade of human 
life [113-115]. The start of lesion development occurs in areas of endothelial dysfunction. 
The endothelial cells become permeable and express adhesion molecules on their surface. 
In stage I lesions, some of the macrophages develop into isolated foam cells after 
ingesting oxidized low density lipoproteins. In stage II lesions, the lipids accumulate 
within the smooth muscle cells, the macrophage foam cells accumulate and both cell 
types form distinct layers that are seen grossly as fatty streaks. The accumulation of 
macrophages stimulates an inflammatory response in the tissue causing increased 
production of cytokines. Stage III lesions contain the same cells and cholesterol esters as 
seen in stage I and II lesions with the addition of extracellular lipid droplets. This 
accumulation of extracellular material is the link between early and advanced stages of 
atherosclerosis. Stages I, II and III can occur during the first three decades of life 
respectively [116]. Advanced stages of atherosclerosis are described by atheromas, 
lesions that disrupt the intimal structure. Stage IV lesions contain a lipid core caused by 
the accumulation of extracellular lipids in a distinct region.  
This core disrupts the normal intima, and tissue remodeling is initiated by 
invasive macrophages and migrating smooth muscle cells. Stage V lesions can develop 
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into three different forms. Type V(a) have multiple layers or cores separated by thick 
fibrous tissue. Type V(b) lesions have a calcified lipid core, causing severe changes in the 
elastic properties of the intima. Type V(c) is used to describe lesions with small or absent 
lipid cores, but with extensive fibrous tissue. Stage VI lesions are stage V and IV lesions 
that have further modifications. Type VI(a) lesions have surface disruptions, type VI(b) 
lesions have either hematoma or hemorrhage associated with the lesion and type VI(c) 
lesions have thrombotic deposits. These different types of surface modification are 
sometimes called complicated lesions [117]. 
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2. Construction and Characterization of Modified Vesicle Design  
Vesicles for targeted drug delivery can be made from several different types of 
materials such as natural or synthetic surfactants, polymers, peptides, minerals and 
metals. Vesicles fabricated from semiconductors and single wall nanotubes have also 
been used as drug carriers [118]. They are very stable and have long circulation times but 
are not biodegradable and present possible long-term health risks. Membrane vesicle 
designs using molecules that self-organize when placed into aqueous solutions and form 
non-covalent structures provide a design that has been used in nature. This is the design 
chosen for this study and the construction is described in the following sections. 
2.1.0 Amphiphiles 
Auto-assembly vesicles and cell membranes are formed from molecules called 
amphiphiles. These are molecules that have two different domains with opposite 
behaviors towards aqueous environments. Amphiphiles have one distinct region that 
attracts water molecules (hydrophilic) while the other region repels water molecules 
(hydrophobic). This property makes them a surface active agent also known as a 
surfactant. Amphiphiles can be made from natural and synthetic surfactants as well as 
peptides and co-block polymers. The molecule properties can be further described by 
their tendency to dissolve in an aqueous liquid (hydrophilicity) or a fatty liquid 
(lipophilicity), known as the hydrophilic-lipophilic balance (HLB). The HLB is 
commonly described on a dimensionless scale where 0 is very lipophilic and 20 is very 
hydrophilic.  
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There are two major classes of surfactants, non-ionic and ionic. The ionic 
surfactants can be cationic (positively charged), anionic (negatively charged) or 
zwitterionic (both positive and negative domains in the head group) that can be positive 
or negative depending on the pH of the solvent. The ionic and non-ionic surfactants have 
hydrophobic tail sections composed of long hydrocarbon chains that are attached to 
hydrophilic head sections with a large hydrodynamic radius compared to the tail section 
as shown in figure 2.0. The difference in the hydrodynamic radius of the head and tail 
section is responsible for the formation of the non-covalent structures made from the 
aggregating surfactant molecules.   
 
Area of hydrophilic 
head group
a =
lengthL =
V = Volume
 
Figure 2.0        Hydrodynamic Shell of a Surfactant Molecule 
One equation describing this basic behavior of the molecule is the non-dimensional 
critical packing parameter (CPP). 
    Equation 2.0 
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In equation 2.0, “V” is the volume of the molecule, “a” is the effective head group area 
and l is the hydrophobic tail chain length. Amphiphiles that have a CPP value below 0.5 
will form micelle structures. Cylindrical micelles will form when the CPP is in the range 
of 0.3 to 0.5. When the CPP range is between 0.5 and 1, amphiphiles will form both 
vesicles and flexible bilayers. Therefore, this is the target range for the surfactants used in 
this study. When the CPP range is equal to 1, then lamella and planar structures are 
formed. Inverse micelles are formed when value of the calculated CPP is greater than 1. 
2.1.1 Non-Ionic Surfactants 
 Non-ionic surfactants are synthetic amphiphiles that are commonly used as 
detergent emulsifiers. The two surfactants used in this study are sorbitan monostearate 
(Span 60) and polyethylene sorbitan monostearate (Tween 61). Both contain fatty acid 
tails composed of approximately equal amounts of stearic acid (CH3(CH2)16COOH) and 
palmitic acid (CH3(CH2)14COOH). Three hydroxyl groups attached to the head groups 
makes the molecules hydrophilic. The Tween 61 molecule has three oligomeric chains of 
polyoxyethylene used to tether the hydroxyl groups to the head of the molecule as shown 
in figure 2.1. 
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Figure 2.1        Molecules: Span 60 and Tween 61 
2.1.2 Cholesterol 
Cholesterol is a steroid which exhibits a slight amphiphilic tendency due to the 
hydroxyl group at the head of the ring structure as shown in figure 2.2. Cholesterol, with 
an HLB factor of 2.96 is used to stabilize the bilayer membrane by adding rigidity due to 
the planar configuration of the molecule. Steroid molecules that are closely related to 
cholesterol, such as β-cholestanol, β-sitosterol and stigmasterol can be used to tailor the 
leakage and stability of the membrane [119]. 
CH3
CH3CH3CH3
CH3
OH
 
Figure 2.2        Cholesterol 
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2.2.0 Polyethylene Glycol 
Polyethylene glycol (PEG) is a hydrophilic polymer made from repeating units of 
ethylene oxide and is shown in figure 2.3. The polymer is also named polyethylene oxide 
(PEO) and polyoxyethylene (POE). PEG is commonly used to refer to polymers with 
molecular weights below 20,000 Da while polymers with molecular weights greater than 
20,000 Da are commonly referred to as PEO. POE is used to describe all weights of the 
polymer. 
OH
O
OH
z  
Figure 2.3        Polyethylene Glycol (PEG) 
The polymer behavior is based on temperature, solvent, molecular weight and the 
concentration of the polymer. When the polymer is synthesized, it may have a 
distribution of molecular weights. Separation techniques are used to sort the polymer 
chains on a size basis. The polydispersity index (PDI) is a measure of how similar the 
molecules are to one another in size and weight (equation 2.3).  It can be calculated by 
the ratio in the number average molar mass (equation 2.1) and the weight average molar 
mass (equation 2.2). 
  = ( ΣniMi / ΣMi )  Equation 2.1 
  = ( ΣwiMi / Σwi )  Equation 2.2 
 PDI =  /   Equation 2.3 
PEG has been used in a variety of drug delivery applications. Conjugation of PEG 
to peptides and proteins is used modify their behavior in the body. Since PEG is highly 
water soluble, it can be used to modify proteins and drugs that are not very soluble in 
aqueous solutions [120]. PEG conjugation can be used to control the membrane 
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permeability of small molecules used as chemotherapeutic agents [121]. It is also used to 
modify protein and peptide circulation time while maintaining bioavailability and 
slowing enzymatic degradation [122-125]. 
PEG can also be conjugated or adsorbed onto the surface of small particles or 
vesicles. The addition of the polymer to the surface helps to slow the attachment of serum 
proteins that tag the particles for removal [126]. This approach has been used in liposome 
production to hide them from phagocytes, creating stealth liposomes [12, 15, 127-135]. 
Another benefit of PEG conjugation is steric stabilization of the particle by physically 
separating the vesicle membranes from one another thereby preventing vesicle fusion 
[136]. 
The conformation of the grafted PEG chains is dependent on the distance between 
surface attachment points (D) and chain length of the polymer (R). There are three 
primary conformations: pancake (D>>R), mushroom (D>R) and brush (D≤R) with 
transition phases between them. For a PEG chain of 2000 Da (PEG 2000), the pancake 
conformation is typical when the PEG surface concentrations are 1.3 mol%. Mushroom 
conformation is found when PEG surface concentrations are at 4.5 mol%. At higher PEG 
concentrations of 9 mol%, the polymer interaction forces the chains to extend into the 
brush conformation [137]. In liposomes, it has been shown that PEG 2000 with a 5 mol% 
surface concentration extends blood circulation times compared to liposomes without the 
PEG chains. For the immuno-niosome vesicle design, a bifunctional PEG 2000 was used.  
2.3.0 Molecule Synthesis 
Vesicles used as drug carriers can be constructed, loaded and functionalized using 
a variety of methods and chemistries. Drug-loaded niosomes that can be functionalized 
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after construction by using a linker molecule activated by adjustment to an alkaline pH, 
provide a functionalization method that is simple and nondestructive to the encapsulated 
therapeutic agent. The surfactant is modified to form a functionalized surfactant molecule 
that can be used to create the niosome vesicles. 
Table 2.0        Immuno-niosome Materials 
Material description Catalog number Manufacturer 
Tween 61 P-3065 Sigma-Aldrich 
Span 60 85546 Fluka 
Omega-Hydroxyl alpha-
amino PEG, MW 2000 Da 
HO-PEG2000-NH2 JenKem Technology Co., 
Ltd. 
Cholesterol 362794-5G Sigma-Aldrich 
N,N-diisopropylethylamine, 
redistilled 
387649-100ML Sigma-Aldrich 
Chloroform AC61028-1000  Acros Organics 
Dicetyl phosphate 101546 MP Biomedicals, LLC 
Cyanuric  chloride C95501  Sigma-Aldrich 
2.3.1  Functionalized Non-Ionic Surfactant 
Polyoxyethylene sorbitan monostearate (Tween 61) is a non-ionic surfactant with 
a fatty acid hydrophobic tail structure composed primarily of stearic acid and a 
hydrophilic head group with three short polyoxyethylene chains. The linker molecule 
cyanuric chloride (CC), is covalently attached to the surfactant through nucleophilic 
substitution to the hydroxyl group on the terminal end of one of the polyoxyethylene 
chains. Tween 61, dissolved in dry chloroform and CC in a 0.8 molar ratio of [CC:Tween 
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61] in the presence of a 3 fold molar ratio of N,N-diisopropylethylamine (DIPEA) are 
mixed together. To form the functionalized surfactant Tween-CC, the mixture is placed in 
a 50 ml round bottom flask attached to a sealed rotary evaporator under a nitrogen 
atmosphere for 36 hours. Next, an intermediate molecule is created by covalently binding 
the amine group on the bi-functional PEG molecule to the previously functionalized 
Tween-CC surfactant in a 0.9 molar ratio [PEG:Tween-CC] in the presence of 2 fold 
molar ratio of DIPEA. To functionalize this intermediate molecule, CC is covalently 
bound to the terminal hydroxyl group on the PEG chain in a 0.8 molar ratio [CC:Tween-
CC-PEG] in the presence of  2 fold molar DIPEA for 36 hours to form Tween-CC-PEG-
CC. The reaction steps are shown in figure 2.4. 
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Figure 2.4        PEGylated Surfactant Synthesis 
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2.3.2  Functionalized Cholesterol 
In addition to the functionalized PEGylated molecule described in section 2.3.1, a 
second functionalized molecule was synthesized to provide options for targeted drug 
delivery. Cholesterol is a fat soluble molecule that can be incorporated in vesicles and 
micelles made from non-ionic surfactants. Using functionalized micelles, lipophilic and 
hydrophobic agents that would normally destabilize a bilayer membrane can be delivered 
to a specific target. The cyanuric chloride (CC) functionalized cholesterol provides a site 
for antibody conjugation that is in close proximity to the vesicle surface, thereby 
enhancing the fusibility of the vesicle with the endothelial cell outer membrane. This 
occurs when the vesicle is less than 2nm from the cell surface and provides an additional 
delivery strategy. The synthesis was carried out as previously described. The cholesterol 
dissolved in dry chloroform was reacted for 36 hours with CC in a 1:0.9 molar ratio in the 
presence of DIPEA under a nitrogen atmosphere. The CC replaces the hydroxyl head 
group on the cholesterol molecule forming the molecule cholesterol-CC as shown in 
figure 2.5. 
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Figure 2.5        Functionalized Cholesterol Synthesis 
2.4.0 Vesicle Synthesis  
 Vesicle formation is a multi-step process driven by the reduction of the 
amphiphile surfactant molecule energy state that forms ordered, non-covalent structures 
as described in section 2.1.0. Membrane formation is a process that requires a 
temperature-dependent phase change and mechanical shear forces. The materials used are 
a combination of surfactant, functionalized surfactant, cholesterol and an electrostatic 
agent. The ratios of materials are derived from previous studies where a 1:1:0.01 molar 
ratio of cholesterol, surfactant and an electrostatic agent respectively, provide a stable 
membrane structure. Here, dicetyl phosphate (DCP) is used as the electrostatic agent 
since it provides a slight negative charge which helps the formed vesicles repel one 
another in solution.  
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2.4.1 Thin Film Formation and Hydration 
 The first step in vesicle formation is the production of lamella that are formed 
from the materials in round bottom glass flasks on a rotary evaporator. Functionalized 
and non-functionalized non-ionic surfactants, cholesterol and dicetyl phosphate are 
dissolved in chloroform. The mixture is reduced under a nitrogen atmosphere at low 
pressures. When the solution is reduced to a thin film, the pressure is reduced to 50 bar 
for 2 hours and then purged with nitrogen under atmospheric pressure at 4 L/min to 
remove trace chloroform from the film. 
To form vesicles, the thin films are hydrated using an aqueous solution containing 
a hydrophilic drug or dye. The aqueous solution is placed in a round bottom flask on a 
sealed rotary evaporator that has been purged with nitrogen. The temperature is raised 
above the gel crystalline phase using a hot water bath and a shear force is applied by 
rotation of the flask on a rotary evaporator to separate the lamella into sheets to form a 
combination of multilayer and bilayer vesicles in solution.  
2.4.2 Vesicle Extrusion 
To control the vesicle size distribution, a barrel extruder (LIPEX™, Northern 
Lipids Inc.) and polycarbonate membranes are used. The membranes are commercially 
available with uniform pore sizes ranging from 1um down to 50 nm, allowing control of 
the desired extruded vesicle size. The extruder is surrounded by a water jacket in order to 
maintain the extrusion temperature above the gel crystalline phase. The raw solution of 
multilayer vesicles (MLVs) and bi-layer vesicles (BLVs) is loaded into the extruder and 
pushed across the polycarbonate membranes using high pressure nitrogen gas. Multiple 
passes are performed to create uniform vesicle dispersions in the bulk solution. 
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2.4.3 Size Exclusion Chromatography Introduction 
 Size exclusion chromatography (SEC) is a method used to separate molecules 
from a solution based on their size. Other types of SEC include: gel filtration 
chromatography (GFC)-aqueous system and gel permeation chromatography (GPC) – 
non-aqueous system, used for polymer separation. Both types of SEC use a non-
adsorptive stationary phase to eliminate any reactive process of the sample with the 
stationary phase. The separation process is driven by two primary phenomena, diffusion 
and exclusion. This is accomplished by placing the sample in a column with a porous 
packing material stationary media. The material allows small molecules to diffuse within 
the stationary packing material while the larger molecules are excluded by size, and flow 
freely around the packing material. This difference in traveling time or retention time 
allows for sample separation as shown in figure 2.6. 
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Figure 2.6        Size Exclusion Chromatography 
2.4.3.1     SEC Volumetric Theory 
The separation process is based on the variation in hydrodynamic sizes of the 
sample molecules to be processed and their interaction with the packing material. The 
porosity of the packing material and the packing geometry create the volumetric 
parameters that are used to describe how the sample elutes from the column.  
  
-
-
 Equation 2.4 
This volumetric distribution is described by equation 2.4, where Kav is the average 
volumetric distribution coefficient, Ve is the elution volume, Vt is the total volume, or 
the sum of the outer (Vo) and the inner volume (Vi) of the packing material, sephadex. Vi 
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is the inner volume of the packing material and is equal to Vt-Vo. Ve-Vo is the retention 
volume and if the packing material particles do not retain the solute (sample), then the 
value of Kav=0. A graphical depiction is shown in figure 2.7. 
 
Figure 2.7        Size Exclusion Chromatography Elution Profile 
2.4.3.2     SEC Methods 
In fluorescent dye loaded niosome production, the formed vesicles must be 
separated from the free (unencapsulated) dye. The bulk sample containing dye-loaded 
niosomes and free dye is injected in a column that is packed with small porous spheres 
made from cross-linked dextran (Sephadex). To prevent the vesicles from collapsing or 
swelling, the aqueous solvent phase used is phosphate buffered saline solution with the 
same osmotic strength as the dye solvent. An Akta Prime (GE Healthcare) 
chromatography system equipped with a pH probe, conductivity probe, pressure sensor, 
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mercury lamp and UV filter set is used for the separation. The column is a 70 cm model 
XK 16 and is used for separating large bulk samples up to 2 ml, however we have found 
that sample sizes of 500 ul avoid fouling in the entrance, causing back mixing of the 
sample. Figure 2.8 is the elution profile of a 2 ml sample where the peak spread from 
where the sample clogged the packing material as it entered the column. 
 
Figure 2.8        Elution Profile from 2 ml Sample Size 
Figure 2.9 is the elution profile from a 500 ul sample that was injected into the column. 
The narrow peak shows that the sample was able to pass through the entrance without 
fouling the packing material to the point that causes back mixing of the sample. 
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Figure 2.9        Elution Profile from 500 ul Sample Size 
2.4.4    Antibody Conjugation 
Immuno-niosomes are created when antibodies are conjugated to the exterior 
surface of the niosomes. This procedure is conducted at room temperature (25°C) on an 
orbital shaker table for 16 hours. First, the conjugation is initiated by adjusting the pH of 
the niosome solution to 8.8 as described by Bendas and Hood [16, 17]. At pH 8.8, the 
chloride groups on the cyanuric chloride molecule are activated and thus a covalent bond 
is formed via nucleophilic substitution with one of the disulfide groups on the Fc region 
of the IgG as shown in figure 2.10. 
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Figure 2.10        Antibody Conjugation 
After antibody conjugation, the solution is loaded in a disposable PD-10 
chromatography column packed with sephadex G-25. The immuno-niosome fraction is 
eluted with one column volume of 0.01M phosphate buffered saline. The pH of the 
sample is verified and adjusted if necessary. The excess unconjugated antibodies can be 
recovered by subsequent column elution.  
2.5.0 Vesicle Metrology 
To determine vesicle size stability and dispersion properties, a variety of methods 
were used to gather data on the niosomes after synthesis. The methods include 
chromatography, microscopy, flow cytometry and dynamic light scattering techniques.   
2.5.1 Thin Layer Chromatography Introduction 
 Thin layer chromatography (TLC) provides an economical method of sample 
analysis without the need for expensive equipment and materials typically used in high 
performance liquid chromatography (HPLC). Although HPLC is more sensitive and can 
detect trace concentrations it is recommended as a follow-up procedure to TLC. TLC is 
also recommended for development and optimization of the solvent system used for the 
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separation. The flat plates allow for visual inspection of the separation. Samples that have 
components that interfere with the separation or are at concentrations below the limit of 
detection will need to be preprocessed by separation or concentration respectively prior to 
using TLC. Separation can be completed using a simple solvent partitioning procedure 
(Folch method, [138]), ion exchange columns [139] or solid phase extraction columns 
[140].  
The TLC separation process is based on a mobile phase composed of a 
combination of solvents that carry the sample up the plate by convective forces and a 
stationary phase acting as the adsorbent and attracting the sample to the matrix by 
hydrogen bonds and dipole interactions. The solvent system contains polar and nonpolar 
solvents creating an organic/inorganic partition on the plate. The sample is separated into 
its components as the mobile phase moves up the plate. 
2.5.1.1     Thin Layer Chromatography Methods  
Table 2.1        TLC Materials 
Item Description Manufacturer 
TLC Plates 20 x 20, Silica Gel 60Å , 250um 
Fluorescent Indicator. 
Whatman® 
Catalog No: 4861-820  
TLC Tank Glass 25 cm x 25 cm Tank Fisher 
Micro-Pipettes 1 Lambda (1 ul) Drummond # 1-000-0010 
Micro-Pipettes 5 Lambda (5 ul) Drummond # 1-000-0050 
Atorvastatin Atorvastatin Calcium Pfizer 
Chloroform Solvent Fisher 
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Table 2.1 (Continued)  
Item Description Manufacturer 
Diethyl Ether Solvent Fisher 
Hexane Solvent Fisher 
Acetic Acid Solvent Fisher 
Methanol Solvent Fisher 
UV Lamp 254nm Ultraviolet hand held lamp Cole Parmer 
Camera 35mm SLR digital , EOS 20D Cannon  
For the TLC separation, 20x20 cm glass plates coated with a thin layer of silica 
(stationary phase) impregnated with a fluorescent indicator were used. When the TLC 
plate is exposed to ultraviolet light, the separated components block the fluorescent signal 
as indicated by a dark spot on the plate. If the component of interest does not fluoresce or 
absorb, a stain can be applied to the plate which will react with or stain the separated 
component so it can be imaged.  
Atorvastatin calcium was encapsulated in a previously designed immuno-
niosome. TLC analysis was used to determine the actual concentration of atorvastatin 
calcium within the immuno-niosomes. Some of the samples were processed prior to TLC 
separation to concentrate and separate components. Standards were applied directly to the 
plate using disposable glass capillary tubes (microcap). Two solvent systems were 
chosen. The first separation was completed in chloroform (a proton donor), methanol 
(polar) and 4% acetic acid in a [45:55:4] volumetric ratio. The second development was 
completed using hexane (as the diluent), diethyl ether (proton acceptor), and acetic acid 
in a [80:20:1.5] volumetric ratio. The methanol and chloroform form a partition on the 
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plate based on their polarity. The hexane and ether are used to separate lipids and 
cholesterol. The acetic acid is used as a solvent modifier to reduce tailing of the sample 
during separation when lipids are present. 
2.5.1.2     Thin Layer Chromatography Results 
The plates are analyzed using an open software routine in MATlab, that 
determines the spot density from an image (shown in Figure 2.11) taken with a 35mm 
SLR digital camera [141]. The plate is illuminated by a mounted 254nm lamp. The focal 
distance of the camera, position of the lamp and position of the sample spot are held 
constant. 
 
Figure 2.11        TLC Image Analysis 
 The calibration curve in Figure 2.12 was generated using known concentrations of pure 
atorvastatin dissolved in methanol. The standards were directly spotted onto the TLC 
plate and then developed. The linearity of the standards (R
2 
=0.9898) shows the sample 
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follows the Beer-Lambert law [142]. Standards and unknowns are included on each TLC 
plate to allow for comparison between plates. To determine the actual encapsulation of 
atorvastatin used to treat apolipoprotein E knockout mice, immuno-niosome samples 
were dehydrated on a vacuum concentrator and reconstituted using methanol. The 
atorvastatin dissolves freely in methanol while cholesterol and Span 60 (niosome 
components) do not. Samples were rehydrated in 1/10
th
 the volume of the original sample 
in order to concentrate the drug. Additionally, standards were separated on the same plate 
to provide a concentration reference. It was determined that the concentration of 
atorvastatin encapsulated in the immuno-niosomes was 1.68E-05 mg/ml, well below the 
expected concentration of 0.15 mg/ml. 
 
Figure 2.12        Atorvastatin Standards  
2.5.2 Fluorescent Microscopy 
 Fluorescent microscopy is used to confirm specific binding of the immuno-
niosomes to cell surface receptors. The antibody conjugation to the immuno-niosomes is 
also imaged using this technique. Materials may exhibit fluorescent behavior when they 
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have been excited by a beam of light. Fluorescence was first described by Stokes when he 
noticed that some minerals emitted visible light when an invisible source light was used 
to illuminate them [143]. This process can be described in three steps using a simple 
Jablonski diagram (Figure 2.13).   
 
Figure 2.13        Jablonski Diagram 
First, the energy state of the molecule is increased by the absorption of light from a 
source. The second step is the release of a photon from the molecule after it has been 
excited by an external source. The third step is the energy level drop to the normal state 
after the release of a photon. This energy difference between the two states is called the 
“Stokes shift” and was described by Alexander Jablonski in 1935 [144]. Fluorescence 
microscopy takes advantage of the ability to separate a specific spectrum of light that is 
emitted from a molecule by using optical filters. To confirm antibody conjugation to the 
functionalized surfactant, large vesicles (>1um) were produced with 5% functionalized 
PEG2000 to create the PEGylated immuno-niosomes. Immuno-niosomes conjugated with 
fluorescein isothiocyanate (FITC) labled antibodies are shown by the arrow in figure 2.14 
(400X magnification). 
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Figure 2.14        PEGylated FITC Conjugated Immuno-niosomes 
Another type of functionalized molecule was synthesized to provide alternative 
conjugation strategies that are described in section 5.3.0. This was accomplished using 
cholesterol and functionalizing the molecule with the cyanuric chloride linker chemistry. 
Confirmation of the functionalized cholesterol was accomplished by imaging large 
vesicles (>1um) that were conjugated with fluorescently tagged antibodies. Figure 2.15 is 
a black and white image taken of the fluorescent tagged immuno niosomes made with 
10% functionalized cholesterol (200x magnification, bright spots indicate fluorescent 
tagged immuno-niosomes). 
 
Figure 2.15        FITC Conjugated Immuno-niosomes Using Functionalized Cholesterol 
 
 
100um 
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2.5.3 Flow Cytometry 
 Flow cytometry is a technique used to examine cells and microscopic particles in 
suspension. For the experiments shown below, an LSR II flow cytometer (Becton 
Dickinson) was used. Cells or particles are either tagged with a fluorescent labeled 
antibody or a fluorescent dye can be encapsulated in the particles. The particles are 
suspended and move in a flowing stream through a laser path. Median fluorescent 
intensity and forward and side scatter from the dye and particle is detected using a 
photomultiplier tube. Forward scatter data is used to indicate cell volume and side scatter 
data is used to examine the complexity of internal structures of the cell or particle. Flow 
cytometry is commonly used to count fluorescently labeled cells in a mixed population. 
In this study it was used to confirm antibody conjugation and provide a map of the 
population distribution of the vesicles, to confirm data collected using dynamic light 
scattering instrumentation. Immuno-niosome samples were conjugated with Fluorescein 
isothiocyanate (FITC) labeled goat anti rat IgG antibodies. Figures 2.16 and 2.17 and 
tables 2.2 and 2.3 show forward and side scatter data along with median fluorescence 
intensity for the two populations from a sample of 5% PEGylated immuno-niosomes that 
were hydrated with phosphate buffered saline and conjugated with FITC labeled IgG. 
Figure 2.18 is dynamic light scattering data for the same sample illustrating the two 
different size vesicle populations. Previously the immuno-niosomes size was controlled 
using extrusion techniques and size exclusion chromatography. By combining these size 
and purification techniques 99.7% of the population was the same size.  
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Figure 2.16        5% PEG Sample Forward Scatter Distribution 
 
Figure 2.17        5% PEG Sample Particle Size Distribution 
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Figure 2.18       5% PEG Sample Dynamic Light Scattering Data 
Table 2.2        5% PEG Sample Event Population 
 
Table 2.3        5% PEG Sample Median Distribution 
 
Fluorescent dye loaded niosomes were prepared using 10% functionalized 
cholesterol. To maintain large vesicle sizes, the niosomes were not extruded. However 
they were vortexed to create large vesicles and then separated from the free dye using 
P1 P2 
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size exclusion chromatography. The different sized fractions were mixed together. 
Forward scatter data illustrating the three different population sizes is shown in figure 
2.19 and table 2.4. The three different population sizes are also shown using dynamic 
light scattering as shown in figure 2.20. 
Table 2.4        10% Functionalized Cholesterol Median Population 
 
 
Figure 2.19        10% Functionalized Cholesterol Forward Scatter Distribution 
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Figure 2.20        10% Functionalized Cholesterol Sample Dynamic Light Scattering Data 
2.5.4 Transmission Electron Microscopy 
Transmission electron microscopy (TEM) is used to provide sample images with 
high resolution and magnification that cannot be achieved with light microcopy. This is 
accomplished in a device that shoots a focused beam of electrons through the sample. 
The signal can be detected using an electronic camera or the resulting beam can be 
viewed on a phosphorus screen. A beam of high energy electrons emanate from an 
electron gun that is passed through a very thin section of material to produce images. The 
electron beam must be under vacuum to prevent unwanted molecular interactions. 
Table 2.5        Transmission Electron Microscopy Materials 
Item Description  Manufacture 
2% glutaraldehyde Fixative made from 50% 
stock 
Fisher 
2% Osmium Tetroxide Fixative and contrast stain EMS 
P1 
P2 
P3 
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Table 2.5 (continued) 
2% Uranyl Acetate Stain EMS 
Acetone Solvent Fisher 
Ethanol Anhydrous agent Fisher 
Propylene Oxide Solvent EMS 
Embed 812 Resin EMS 
Araldite 502 Resin EMS 
Dodecenyl Succinic 
Anhydride 
Anhydride EMS 
2,4,6-tridimethylamino 
methyl phenol (DMP-30) 
Accelerator EMS 
Lead Nitrate Stain EMS 
Sodium Citrate Stain EMS 
1N Sodium Hydroxide Reagent Fisher 
20nm Gold Particles Electron dense marker EMS 
5nm Iron Oxide particle Magnetic particle Oceannanotech 
Copper Grids Sample holder TEM  EMS 
Formvar Coated Grids Sample holder TEM EMS 
A transmission electron micrograph of the solution containing 5% PEGylated 
surfactants hydrated with 0.01M phosphate buffered saline is shown in figure 2.21 The 
solution was stained with uranyl acetate, placed on a formvar coated carbon grid and 
imaged. The arrows indicate multi-layer membranes from the vesicles in the bulk 
solution. 
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Figure 2.21        TEM of Bulk Solution 
A transmission electron micrograph of niosomes prepared with 5% PEGylated 
surfactant and hydrated with 0.01M phosphate buffered saline is shown in figure 2. The 
vesicles were treated with osmium tetroxide to stabilize the vesicle membrane through 
chemical fixation. The vesicle suspension was placed on a formvar coated carbon grid, 
dried and imaged.  
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Figure 2.22        TEM of Extruded 5% PEGylated Niosomes 
A transmission electron micrograph of 5% PEGylated surfactant niosomes containing 
5nm paramagnetic FeO particles in 0.01M phosphate buffered saline is shown in figure 
2.23. The vesicle suspension was placed on a formvar coated carbon grid, dried and 
imaged.  
 
Figure 2.23        TEM of 5% PEGylated FeO-Loaded Niosomes 
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2.5.5 Dynamic Light Scattering 
Dynamic light scattering (DLS) is also known as photon correlation spectroscopy 
(PCS) or quasi-elastic light scattering (QLS). DLS uses the physics of small particle 
behavior to correlate data from light scattered by the particles in solution [145, 146]. The 
sample is placed into a cuvette and a monochromatic light source such as a laser is passed 
through the sample (figure 2.24). The scattered light that has collided with the particles in 
the sample is collected and the data is analyzed.  
 
Figure 2.24        Dynamic Light Scattering 
The theory of dynamic light scattering is based on Brownian motion caused by 
thermal energy causing random motion of a particle in solution. For spherical particles 
the relationship of the radius and the diffusion coefficient (equation 2.5) is given by the 
Stokes Einstein equation [147], where the diffusion coefficient (D) is equal to the 
mobility of the particle (μp) multiplied by Boltzmann’s (kB) constant and the absolute 
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temperature (T). The mobility (equation 2.6) of a particle is the ratio of the particle’s 
terminal drift velocity (Vp) to an applied force (F). The Boltzmann’s constant (equation 
2.7) relates the energy of the microscopic particle to the energy level of the macroscopic 
surroundings. It is the gas constant (R) divided by Avogadro’s number (NA). Applying 
Stokes law for frictional force (Fd) (equation 2.8), the drag coefficient γ is formed 
(equation 2.9) with R being the particle radius and μ being the viscosity of the fluid. 
Using Stokes law, the Einstein equation becomes a relationship of the apparent diffusion 
coefficient and the radius of the particle (equation 2.10) that can be rearranged to yield 
the apparent radius of a particle when the diffusion coefficient is known (equation 2.11) 
[148]. 
 D = μpkBT   Equation 2.5 
 μp= Vp / F   Equation 2.6 
 kB= R / NA = 1.38E-23 [JK
-1
]  Equation 2.7 
 Fd = 6πRVμ   Equation 2.8 
 γ = 6πRμ   Equation 2.9 
 D = (kB T) / (6π R μ) [m
2
s
-1
]   Equation 2.10 
 RApp = (kB T) / (6π μ DApp)   Equation 2.11 
In dynamic light scattering data analysis, the light scattered from the sample is 
used to determine the time it takes for the particle to move from its original starting 
position. The correlation function is used to relate the change in time and the difference 
of the current position of the particle compared to its original position. At low 
concentrations, the correlation function can relate the size of the particle to the 
temperature and the viscosity of the fluid. A graph of the correlation function for a 
71 
niosome sample is shown in figure 2.25. On the left side near time =0, the correlation of 
the position of the particle to its original position is equal to one, meaning the starting 
position of the particle is directly related to its current position. As time increases, this 
relationship is eventually lost and there is no correlation of the current position of the 
particle to where it originated. The rate of decay is used to calculate the radius of the 
particles. 
 
Figure 2.25        Niosome Sample Correlation Data  
Niosomes containing Span 60 and 10% Tween or Span 60 and 5% PEG, were 
placed in sealed cuvettes and measured every 7 days over a 90 day period. Care was 
taken not to disturb the samples during the time course and particle sedimentation was 
noted in the non-PEGylated niosome samples. The results from these data suggest the 
PEG had a positive effect in maintaining vesicle suspension and size dispersion, shown in 
figure 2.26 
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Figure 2.26        Data from Stability Comparison Study on Day90  
  
5% PEG 
10% Tween 
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3. Evaluation of Receptor-Conjugated Vesicles 
Binding studies were conducted to investigate immuno-niosome interactions with 
endothelial cells. Several methods were used to gather data to ensure the results were not 
biased by the detection technique. Most of the techniques were based on an encapsulated 
fluorescent dye to detect the cell bound immuno-niosomes. Gold particles were 
encapsulated for transmission electron microscopy experiments. 
3.1.0 Cell Culture 
Primary bovine aortic endothelial cells (BAEC) and endothelial basal media 
(EBM-2) were purchased from Lonza. The cells were plated at an average density of 
6.7x10
5
 cells/cm
2
 and grown in T-25 culture flasks (Costar) using EBM-2 supplemented 
with 10% heat inactivated calf serum and 100 units/ml penicillin and 100 ug/ml 
streptomycin in a humidified 5% CO2/95% air incubator at 37°C. When the cells reached 
85% confluency, aliquots were frozen back in a 50:50 (V:V) mixture of supplemented 
EBM-2 and DMSO supplemented cryopreservative (Profreeze, Cambrex Bio Science).  
Endothelial cells used in binding experiments were allowed to proliferate in tissue 
culture flasks to a cell viability of 98% prior to high density plating and were used from 
passage 2 to passage 5. The cells were rinsed three times with 0.01M phosphate buffered 
saline solution (PBS) and then were detached from the flask bottom using 4% 
trypsin/EDTA in 0.01M PBS for 2 minutes. The cells were collected and resuspended in 
serum-supplemented EBM-2 to neutralize the trypsin. The suspension was centrifuged at 
900 Gs to form a cell pellet. The cell pellet was resuspended in fresh supplemented EBM-
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2 and plated onto growing surfaces of choice, i.e. flasks, glass slides, glass cover slips or 
96 and 24 multi-well plates.  The glass slides and cover slips were cleaned with 100% 
ethanol (ETOH) and dried prior to steam sterilization. For some experiments, the glass 
surfaces were treated with sterile 1M NaOH for 30 minutes and rinsed with 0.1M PBS 
three times to improve cell adhesion. 
3.2.0 Fixed Cell Binding 
Fixed endothelial cells under static conditions were used to determine the binding 
efficiency of the PEGylated immuno-niosomes (INs) to endothelial cells. For receptor 
specific binding, the cells were treated with the cytokine, tumor necrosis factor alpha 
(TNF-α), to invoke an inflammatory response in the endothelial cells for expression of 
the targeted cell surface receptors. This was accomplished by treating the cells with 20 
ng/ml TNF-α in supplemented EBM-2 for 24 hours before the experiment. After 
incubation with TNF- α, the cells were chemically fixed to preserve the receptors to 
prevent internalization or turnover of the expressed receptors over long time courses. The 
cells were fixed with a solution made from 2% glutaraldehyde in 0.01M PBS to maintain 
the osmotic balance in the sample. The fixation causes cross linking between protein 
molecules. Glutaraldehyde was used for the fixation because it is a larger molecule than 
formaldehyde and is able to bridge greater distances. For some experiments the 
commercial preservative Histochoice was used since it has less auto-fluorescence signal 
than glutaraldehyde. After fixation, the cells were rinsed three times with 0.01M PBS. 
Some PBS was left on the cells after the last rinse to maintain sample moisture. It was 
removed just prior to immuno-niosome sample application.  
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The niosome concentration is indicated by the total surfactant content of the 
sample. Black plastic 96 well culture plates with clear bottoms were used for the 
experiments using fluorescent dye to reduce signal cross talk between wells. BAEC were 
plated and grown as previously described in section 3.1.0. The cells were treated with 
TNF-α for 24 hours, fixed and the treated with a 2% solution of normal goat serum in 
0.01M PBS to block nonspecific binding. The cells were then incubated with fluorescein-
loaded immuno-niosomes that were conjugated with CD44, clone KM201. The 
PEGylated immuno-niosomes were compared to the previous immuno-niosome design to 
determine the effect of the PEG tether used for antibody conjugation. The endothelial 
cells were incubated for 5, 10, 15, 30, 60 and 120 minutes with 1.5, 3, and 6 mM of 10% 
Tween immuno-niosomes or 5% PEGylated immuno-niosomes at 37°C. Following 
incubation, each cell well was rinsed three times with 0.01M PBS to remove unbound 
immuno-niosomes. The plate was imaged on a Typhoon 9410 flat bed fluorescent 
scanner (GE Healthcare) using the 488nm laser to excite the fluorescent dye. Data was 
collected at 528nm with a setting of 600volts on the photomultiplier tube, a pixel size of 
100 microns and a focal plane of 3mm to account for the distance from the bottom of the 
plate to the imaging surface. The cell density was determined by treating the cells with a 
solution of 20ng/ml propidium iodide and using excitation/emission of 535/620nm on the 
Typhoon. The raw data was analyzed with Quantity One software. For each well, the 
fluorescent volume was calculated by taking 5 mm regions of interest at 5 different 
locations. The error bars in figures 3.0 and 3.1, indicate the standard deviation for the 
measurement. The results from the vesicle comparison study showed an increase in the 
binding performance of the 5% PEGylated INs over the previous 10% Tween IN design. 
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This was most evident with the higher vesicle concentration and longer incubation times. 
The results of the vesicle comparison study are shown in figures 3.0 and 3.1, and the data 
is summarized (percent difference in binding) in table 3.0.  
 
Figure 3.0        Fixed Cell Binding: 10% Tween Fluorescein-loaded IN (CD44, KM201) 
 
Figure 3.1        Fixed Cell Binding: 5% PEG Fluorescein-loaded IN (CD44, KM201) 
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Table 3.0        Static Binding Results 
 
 
 
 
 
 
 
 
 
3.3.0 Live Cell Binding 
We sought to determine how the immuno-niosomes interacted with live cells and 
to confirm BAEC uptake of the immuno-niosomes using CD44 as the target receptor. A 
study comparing the CD44 receptor to other receptors was conducted using 
carboxyrhodamine 110 fluorescent dye loaded immuno-niosomes conjugated with CD44, 
ICAM-1 or VCAM-1 antibodies. Confocal microscopy was used to confirm uptake using 
the CD44 receptor and to examine binding patterns between ICAM-1 and CD44 INs 
binding to the BAEC. 
3.3.1 Multiwell Plate Experiments 
 Two different experiments were conducted using live cells grown in multiwell 
plates to provide IN and active cell surface receptor binding data. For both experiments 
the cells were grown and plated as previously described in section 3.1.0. In the first 
experiment, cells were plated in black plastic 96 well tissue culture plates with clear 
Time 
[minutes] 
6mM % 
Diff. 
3mM % 
Diff. 
1.5mM % 
Diff. 
5 1.21 0.84 2.12 
10 1.16 1.82 1.73 
15 3.11 0.44 4.63 
30 1.93 2.10 6.37 
60 10.76 8.03 7.96 
120 17.00 9.25 12.82 
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bottoms and grown until they were 85% confluent. This experiment was designed to 
determine if antibodies that target different receptors have similar nonspecific binding 
properties. To determine nonspecific binding, the cells were not treated with cytokines 
prior to incubation with the immuno-niosomes. The immuno-niosomes were conjugated 
with ICAM-1, VCAM-1 or the CD44 antibody. A control vesicle was not conjugated 
with antibodies. A 3mM immuno-niosome solution in Dulbecco’s Modified Eagle 
Medium (DMEM) was used for the experiment. Cells were incubated with immuno-
niosomes or control vesicles for 0.5, 1.0, 2.0 and 4.0 hours in a humidified 5% CO2/95% 
air incubator at 37°C. 
Each cell well was rinsed three times with 0.01M phosphate buffered saline (PBS) 
to remove unbound vesicles. The plate was imaged on a Typhoon 9410 flat bed 
fluorescent scanner (GE Healthcare) using the 488nm laser to excite the fluorescent dye. 
Data was collected at 528nm with a setting of 600volts on the photomultiplier tube, a 
pixel size of 100 microns and a focal plane of 3mm. The cell density was determined by 
treating the cells with a solution of 20ng/ml propidium iodide and imaging using an 
excitation/emission of 535/620nm on the Typhoon. The results of the experiment indicate 
that the nonspecific binding is antigen independent as shown in figure 3.2 
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Figure 3.2        Nonspecific Binding Results 
 The second experiment was designed to compare the binding performance of the 
different receptor-targeted immuno-niosomes to live cells. The cells were plated in black 
plastic 24 well tissue culture plates with clear bottoms and grown until they were 85% 
confluent. Control cells were not treated while the other cells were treated with 20ng/ml 
TNF-α for 24 hours. Then all the cells were treated with a 2% solution of normal goat 
serum in 0.01M PBS to reduce nonspecific binding prior to incubation with the immuno-
niosomes. The immuno-niosomes were conjugated with ICAM-1, VCAM-1 or the CD44 
antibody. A control vesicle was not conjugated with antibodies. A 1.5mM immuno-
niosome solution in DMEM was used in the experiment. Cells and antibody conjugated 
immuno-niosomes or control vesicles were incubated for 1, 2 and 4 hours in a humidified 
5% CO2/95% air incubator at 37°C. Each cell well was rinsed three times with 0.01M 
phosphate buffered saline (PBS) to remove unbound vesicles. The plate was imaged on a 
Typhoon 9410 flat bed fluorescent scanner (GE Healthcare) using the 488nm laser to 
excite the fluorescent dye. Data was collected as previously described. The cell density 
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was determined by treating the cells with a solution of 20ng/ml propidium iodide and 
imaging using an excitation/emission of 535/620nm on the Typhoon. The results of the 
experiment indicate that by four hours post-immuno-niosome binding, the three antigens 
have similar binding to the endothelial cells as shown in figure 3.3. 
 
Figure 3.3        Live Binding Performances 
3.3.2 Confocal Laser Scanning Microscopy 
Confocal microscopy was used to determine binding characteristics of the 
immuno-niosomes (INs) to activated bovine aortic endothelial cells (BAECs). Confocal 
microscopy uses multiple focal planes, called the z-stack to reconstruct images. Each 
plane is scanned with a focused beam of laser light. This is accomplished one line at a 
time over the surface from one end of the image to the other. The software that 
reconstructs the images uses a setting called maximum projection. This setting uses the 
maximum average intensity from each plane to reconstruct the compiled image. This 
method is an improvement over standard fluorescent microscopy since data from the out-
of-focus plane is not used, providing better image contrast and resolution. 
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Two types of experiments were conducted using confocal microscopy. The cells 
were grown as previously described in section 3.1.0 and plated in 8 well glass tissue 
culture chamber slides (Lab Tek II, Fisher Scientific). In the first experiment, the cells 
were activated using an injury model. The injury was created by scratching the cells in 
each well in an “x” pattern with a 200ul pipet tip, 24 hours prior to incubation with the 
INs. The INs were loaded with 1mM carboxyrhodamine 110 dye since it is more photo 
stable than fluorescein-based dyes. The INs were conjugated with either ICAM-1 or 
CD44 antibodies and incubated with the injured cells for one hour. The cells were rinsed 
three times with 0.01M phosphate buffered saline (PBS) solution before fixation with 
Histochoice fixative to preserve the cells and bound vesicles. The slides were cover-
slipped with a number 1.5 glass cover and mounting media containing 4',6-diamidino-2-
phenylindole (DAPI) stain to identify the cell nucleus. DAPI is a stain that when bound to 
double stranded DNA fluoresces approximately 20 times greater than DAPI alone. An 
image of the cells and ICAM-1 INs from the injury model is shown in figure 3.4, with 
arrows pointing at the injury border. The fluorescent intensity of across the injury (ROI 
1) is shown in figure 3.5.  
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Figure3.4        One Hour Scratch Injury ICAM (200X Magnification) 
 
Figure 3.5        Graph of Fluorescent Intensity from Region of Interest 1 
The injury model was used to compare the binding of ICAM-1 and CD44 antibodies 
against the receptors expressed by the injured endothelial cells. Figure 3.6 is an image of 
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how the regions of interest were located; the results are shown in table 3.1 (fluorescence 
± standard deviation).  
 
Figure 3.6        Injury Model Region of Interest (200X Magnification) 
Table 3.1        Injury Binding Results 
Pixel Density CD44 ICAM-1 
Injured ROI  1052828(+/-993.21) 383184(+/- 325.96) 
Non Injured ROI 633041(+/-543.01) 179019(+/- 168.65) 
Difference  419787 204165 
Uptake of the antibody conjugated immuno-niosomes into the activated 
endothelial cells was confirmed in the second set of experiments using confocal 
microscopy techniques. The INs were loaded with 1mM Carboxyrhodamine 110 
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fluorescent dye, extruded across 200nm polycarbonate membranes and purified using 
size exclusion chromatography. The dye loaded niosomes had an average size of 168nm 
based on dynamic light scattering data. The INs were conjugated with CD44, ICAM-1 or 
VCAM-1 antibodies. The cells were grown as previously described in section 3.1.0 and 
plated in 8 well glass tissue culture chamber slides and grown until they were 85% 
confluent. The cells were treated with 20 ng/ml TNF-α for 24 hours before being treated 
with a 2% solution of normal goat serum in 0.01M PBS for one hour to reduce 
nonspecific binding prior to incubation with the immuno-niosomes. The cells were 
incubated with a 3mM solution of immuno-niosomes in Dulbecco’s modified eagle 
medium (DMEM) for 1, 2, 3 and 4 hours. The cells were rinsed three times with 0.01M 
PBS before fixation with Histochoice fixative to preserve the cells and bound vesicles. A 
5 ug/ml solution of wheat germ agglutinin conjugated to Alexa Fluor 633 (WGA Alexa 
Fluor 633, Invitrogen) in 0.01M PBS was used to stain the cell membrane. The slides 
were cover-slipped with a number 1.5 glass cover-slip and mounting media containing 
4',6-diamidino-2-phenylindole (DAPI) nucleic acid stain to identify the cell nucleus. In 
figures 3.7 through 3.13, the carboxyrhodamine 110 fluorescent dye is shown in green. 
Figures tagged with an (A) indicate TNF-α activated endothelial cells and figures tagged 
with a (B) indicate control endothelial cells that were not treated with TNF-α. 
Internalized dye within the cell is indicated by the arrow in figure 3.7(A). Endothelial 
cells with no injury or TNF-α treatment served as the control as shown in figure 3.7(B). 
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Figure 3.7        (A) 4 Hour PEGylated CD44 Immuno-niosomes, (B) Control, 4 Hour 
PEGylated CD44 Immuno-niosomes, (630X Magnification)  
 
Figure 3.8        (A) 3 Hour PEGylated CD44 Immuno-niosomes, (B) Control, 3 Hour 
PEGylated CD44 Immuno-niosomes, (630X Magnification) 
A B 
A B 
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Figure 3.9        (A) 2 Hour PEGylated CD44 Immuno-niosomes, (B) Control, 2 Hour 
PEGylated CD44 Immuno-niosomes, (630X Magnification) 
 
Figure 3.10        (A) 1 Hour PEGylated CD44 Immuno-niosomes, (B) Control, 1 Hour 
PEGylated CD44 Immuno-niosomes, (630X Magnification) 
Figures 3.8 (A and B) shows endothelial cells that were incubated for 3 hours 
with PEGylated CD44 conjugated immuno-niosomes. The arrows point at immuno-
niosomes that have formed clusters on lipid rafts on the cellular membrane as they are 
being internalized. Figures 3.9 (A and B) show endothelial cells that were incubated for 2 
hours with PEGylated CD44 conjugated immuno-niosomes. The clusters of immuno-
niosomes have formed, but they are not as distinct as the clusters in the 3 and 4 hour 
incubations. This suggests that the endocytotic pathway involves lipid rafts and clustering 
of cell surface receptors. Figures 3.10 (A and B) show endothelial cells that were 
A B 
A B 
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incubated for 1 hour with PEGylated CD44 conjugated immuno-niosomes. The immuno-
niosomes are bound to the cell surface but have not formed clusters as seen with longer 
incubation times. Internalization is confirmed by the Z-stack images shown in figure 3.11 
(A-D) showing the internalized dye in the 1-4 hour treated samples (A) from figures 3.7-
3.10. 
 
Figure 3.11        (A-D) Z-stack of the 1-4 Hour PEGylated CD44 Immuno-niosomes, 
(630X Magnification) 
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To compare immuno-niosome binding to endothelial cells using a different 
antigen. PEGylated niosomes were conjugated with VCAM-1. Endothelial cells 
incubated for four hours with PEGylated VCAM-1 conjugated immuno-niosomes are 
shown in figures 3.12 (A and B). The arrows point at immuno-niosomes that have formed 
clusters on lipid rafts on the cell membrane, similar to PEGylated immuno-niosomes that 
were conjugated with CD44.  
 
Figure 3.12        (A) 4 Hour PEGylated VCAM-1 Immuno-niosomes, (B) Control, 4 Hour 
PEGylated VCAM-1 Immuno-niosomes, (630X Magnification)  
Confocal microscopy was also used to image immuno-niosomes made from 
functionalized cholesterol. The steroid was functionalized with cyanuric chloride as 
previously described in section 2.3.2 and immuno-niosomes were made with 10% 
functionalized cholesterol loaded with 1mM carboxyrhodamine 110 and conjugated with 
ICAM-1 antibodies. The cells were grown and plated in 8 well glass tissue culture 
chamber slides. They were treated with 20 ng/ml TNF-α followed by 2% goat serum 
prior to incubation with immuno-niosomes as previously described. Figure 3.13 (A) and 
(B) are images of endothelial cells incubated for 4 hours with immuno-niosomes made 
A B 
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with 10% functionalized cholesterol. The vesicles appear to have formed dense clusters 
on the endothelial cell surface.   
 
Figure 3.13        (A) 4 Hour ICAM Cholesterol Immuno-niosomes, (B) Control, 4 Hour 
ICAM Cholesterol Immuno-niosomes (630X Magnification) 
3.3.3  Transmission Electron Microscopy 
Transmission electron microscopy (TEM) was used to image immuno-niosomes 
loaded with albumin coated 20nm gold nanoparticles. Gold is an electron dense material 
that provides a strong signal when viewed with TEM. The immuno-niosomes were 
conjugated with antibodies that target the CD44 cell surface receptor. Endothelial cells 
were grown in T-25 culture flasks as previously described in section 3.1.0. The cells were 
treated with 20 ng/ml TNF-α in supplemented EBM-2 for 24 hours. The cells were fixed 
with 2% glutaraldehyde in 0.01M phosphate buffered saline (PBS) for 15 minutes. The 
cells were washed three times with 0.01M PBS to remove excess glutaraldehyde. The 
cells were treated with 2% osmium tetroxide (OsO4, a heavy metal compound that is used 
as a fixative and a stain) for 30 minutes and rinsed with deionized water three times to 
remove excess osmium and salts. The cells were removed from the flasks using a cell 
scraper and were recovered by centrifugation at 900g to form a cell pellet.  Since epoxide 
A B 
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resins are not miscible with water, the samples must be dehydrated. To protect the cells 
during this process, the dehydration is done slowly and great care is taken to ensure the 
samples do not dry completely between steps by ensuring the sample is always covered in 
solution. Samples are dehydrated for 2 minutes each step in 20% (v/v), 30%, 50%, 70%, 
90% ethanol at 4°C followed by 100% ethanol at room temperature and 100% ethanol at 
4°C. Prepared resin (Appendix A, note 1) is diluted with solvent in a 1:1 (v/v) ratio. The 
cell pellets are immersed in this solution for one hour and agitated to ensure adequate 
infiltration of the cells. The cells are spun at 900g for 5 minutes to form a pellet and the 
excess resin is removed and replaced with pure resin at room temperature for one hour. 
This step is repeated one additional time. To embed the samples, the cell pellets are then 
placed in labeled casting trays with pure resin and heated to 60°C for 24-48 hours to 
polymerize the resin. 
 Thick sections of the embedded cells are cut and stained with semeithin stain and 
viewed using light microscopy to inspect the samples. Then thin sections, 50-70um, are 
cut from the embedded samples and floated on prepared mesh grids (Appendix A, note 2) 
and placed sample side up for drying in petri dishes lined with filter paper. Uranyl acetate 
(UA) staining of the thin sections is performed by prepping a disposable 4-well petri dish 
with a section of dental wax and adding a drop of prepared UA stain (Appendix A, note 
3) corresponding to each grid to be stained. Grids with samples are placed sample side 
down on the UA stain for 10 minutes. The samples are washed with deionized water in a 
series of three beakers. The grids are agitated by moving the sample vertically in each 
beaker. The washed grids are placed on the filter paper and dried before lead staining. 
Lead staining is performed on dry grids as follows. The petri dish is prepared as 
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previously described. Sodium hydroxide (NaOH) pellets (to remove CO2) are placed in 
the chamber with the dental wax. Prepared lead citrate stain is added (Appendix A, note 
4). The grids are floated sample side down on the drops of lead stain for 1-3 minutes. The 
grids are washed as before in a series of three beakers filled with deionized water and 
allowed to dry sample side up on filter paper. A transmission electron micrograph taken 
at 30kv of gold loaded, internalized PEGylated CD44 conjugated immuno-niosome is 
shown in figure 3.14. The arrow points to gold particles that have been internalized inside 
the endothelial cell. The arrow in figure 3.15 points to a gold loaded PEGylated CD44 
conjugated immuno-niosome bound to the cell membrane. Because gold is not 
metabolized, sections of tissue samples from the liver and spleen (from in vivo 
experiments) would provide information on how the immuno-niosomes interact with the 
organs. 
 
Figure 3.14        Gold Loaded, Internalized Immuno-niosomes 
 
92 
 
Figure 3.15        Gold Loaded Immuno-niosome Bound to Cell Membrane 
3.4.0 pH Sensitive Dye Study 
When the endothelial cell internalizes the targeted delivery vesicle by the process 
of endocytosis, the process can be tracked by using a fluorescent agent that shifts 
spectrum with changing pH conditions. A family of pH sensitive dyes, 
seminaphthorhodafluor-carboxylic acid (SNARF), can be used to track such 
environmental pH changes. [149-156, 157 ]. It was hypothesized that encapsulation of the 
pH sensitive dye could be used to track the different steps associated with vesicle 
internalization [158-161]. It is well understood that cellular internalization pathways 
utilize vacuoles that employ a pH change. This intracellular change creates a condition 
that causes conformational changes in proteins, thus enabling the sorting and recycling of 
cellular receptors to the cell surface. Endocytosis is a multistep process that can involve 
multiple transport vacuoles such as early endosomes, late endosomes and lysosomes 
[162]. This process can be monitored by using an indicator to determine the time course 
of the pH shift in the micro environment. Carboxy SNARF-4 was selected for the study 
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based on reports of SNARF-1 interacting with the liposome membrane [163]. Samples of 
SNARF-4 dye were placed in a steady state spectrofluorometer (ISS PC1) to gather 
spectral data from the dye at different pH values. The stock solution of dye was diluted to 
a 1μM concentration in 0.01M phosphate buffered saline solution and the pH was 
adjusted using 1N hydrochloric acid. The samples were excited at 488nm and the spectra 
of the 1μM SNARF-4 dye, with a pH ranging from 5.45 to 7.2 were recorded as shown in 
figure 3.16.  
 
Figure 3.16        Fluorescence Spectra of 1 μM SNARF-4 in PBS, pH 5.45 to 7.2 
There was a strong pH dependent shift in the SNARF-4 dye spectra. It shifted 
from 650 nm at a pH of 7.2 to 580 nm at pH 5.4. This data suggested the dye could 
indicate the intracellular pH changes in the different cellular compartments. Therefore 1 
μM SNARF-4 dye was encapsulated in niosomes made from Span 60, cholesterol and 
dicetyl phosphate. The samples were then placed into the spectrofluorometer and the 
spectra at various emission wavelengths were recorded. When the SNARF-4 loaded 
niosomes at a pH of 7.2 were excited at 488nm, the spectrum showed a peak at 520 nm 
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(figure 3.16). This result was unexpected, therefore the experiment was repeated using 
new samples of niosomes loaded with SNARF-4 dye. The results of the two experiments 
confirmed the spectra of the SNARF-4 loaded niosomes had a peak at 520 nm when 
excited at 488 nm at a pH of 7.2, as shown in figure 3.17. 
 
Figure 3.17        Spectrum of SNARF-4 Loaded Span 60 Niosomes at pH 7.2 
The spectra of the individual components of the niosomes were recorded to determine the 
source of the 520 nm emission peak. Cholesterol was found to fluoresce with a strong 
signal when placed in 0.01M phosphate buffered saline solution, the same concentration 
was to make niosomes at a pH of 7.2 (figure 3.18). The ring structure of cholesterol 
shown in figure 2.2 is thought to be the source of the signal. 
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Figure 3.18        Spectrum of Cholesterol 
3.5.0 Vesicle Binding in Flow 
 In preparation for in vivo studies, the confirmation of the ability of PEGylated 
CD44 conjugated immuno-niosomes to bind to endothelial cells in flow was confirmed 
using a parallel plate flow chamber (CytoDyne, La Jolla, CA.). The chamber was 
attached to a syringe pump as shown in figure 3.19. 
Flow cell
Glass slide
Syringe pump
Waste
 
Figure 3.19 Flow Cell 
Endothelial cells were cultured as previously described in section 3.1.0. Cells were plated 
at a density of 2x10
3
 total cells on 75 mm x 38 mm glass slides that were steam sterilized 
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and treated with 1M sodium hydroxide. The cells were grown to 80% confluency before 
treatment with 20 ng/ml TNF-α for 24 hours. The cells were fixed with a solution made 
from 2% glutaraldehyde in 0.01M phosphate buffered saline (PBS) and rinsed to remove 
excess glutaraldehyde. A 60 ml syringe was loaded with 0.01M PBS and the system was 
primed with 10 ml PBS to remove any air. The slide was placed on the flooded chamber 
then vacuum was applied to hold the slide in place. Before starting the pump, a 2ml bolus 
injection of a 3mM solution of PEGylated CD44 conjugated immuno-niosomes loaded 
with 5mM 5(6)carboxyfluorescein was injected upstream of the chamber. Then the pump 
was started and 50 ml of PBS was eluted at a flow rate (Q) of 14 ml/min through the 
chamber. Using equation 3.0, the calculated endothelial cell shear stress (τ) was 10.4 
dynes/cm
2
, using a viscosity (μ) of 9x10-3dyn/s*cm2, channel height (h) of 2.2x10-2 cm 
and a channel width (b) of 2.5 cm[164].  
 τ = (6Qμ) / (bh2)   Equation 3.0 
Fluorescence microscopy was used to verify immuno-niosome binding in flow to 
endothelial cells placed in the parallel plate flow chamber. The samples were post stained 
with 4′,6-diamidino-2-phenylindole, dihydrochloride (DAPI) to determine the location of 
the cell nucleus. The arrows in figure 3.20 point at bound vesicles on the endothelial 
cells. 
 
Figure 3.20        PEGylated CD44 Conjugated Immuno-niosomes Bound to Endothelial 
Cells Under Flow Conditions (400x Magnification) 
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4. Enhancement of the Modified Vesicle Designs for Targeted Delivery in Vivo 
To determine the bio-distribution of the immuno-niosomes in vivo it is necessary 
to use a fluorescent dye where there is minimal imaging interference from living tissues, 
e.g. hemoglobin, collagen, cholesterol and water. A near infrared dye with a maximum 
emission spectrum of 800 nm was used (IRDye 800CW carboxylate, LiCor Biosciences).  
4.1.0 Multi Well Plate Imaging 
Free and encapsulated IRDye 800CW was imaged using an in vivo imaging 
system (Xenogen IVIS Spectrum, Caliper Life Sciences). Both epi and trans-illumination 
methods were used to measure fluorescence intensity at excitation/emission 745/800 nm. 
Figure 4.0 shows a 96 well plate with two concentrations of IRDye 800CW (A1-3) 
1nmol, (B1-3) 4 nmol and (C1-3) 0.01M phosphate buffered saline solution (PBS). The 
minimum IRDye 800CW concentration detectable using epi-illumination with a 5 second 
exposure time was 1 nmol.  
 
Figure 4.0        IRDye 800CW Bulk Solutions 
In the next experiment, 0.01M PBS was encapsulated in 5% PEG and 10% Tween 
niosomes (figure 4.1 A1-3 and B1-3 respectively). IRDye 800CW was encapsulated in 
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5% PEG niosomes in 1 nmol (Lane D1-3) and 4 nmol (Lane C1-3) concentrations. Three 
different volumes of the samples, 100 ul (column 3), 200 ul (column 2) and 300 ul 
(column 1) were imaged using epi-illumination (5 second exposure, F2 aperture, small 
binning) and the image is shown in figure 4.2. It was determined that the PBS loaded 
niosomes did not have a signal that would interfere with the dye, and that 4 nmol IRDye 
800CW loaded niosomes were required for imaging at these settings. 
 
Figure 4.1        IRDye 800CW Reference Samples 
Based on these results, niosomes were loaded with 4 nmol IRDye 800CW, extruded 
across 200 nm polycarbonate films and purified using size exclusion chromatography 
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(SEC) as described in Section 2.4.3. Three volumes of 4 nmol IRDye 800CW loaded 
niosomes, 300, 200, 100 ul (Row A, B, C respectively in Figure 4.2) were imaged to 
confirm previous results The results shown in Figure 4.2 show that the method is 
repeatable and that extruded, SEC purified niosomes loaded with 4 nmol IRDye800CW 
can be imaged using epi-illumination on the Xenogen IVIS Spectrum.  
 
Figure 4.2        4nmol IRDye 800CW Loaded 5% PEGylated Niosomes 
4.2.0 Phantom Mouse Imaging 
To determine preliminary concentrations of fluorescent dye and immuno-
niosomes for in vivo studies, a synthetic mouse called the phantom mouse was used to 
image samples of niosomes loaded with the IRDye800CW fluorescent dye. IVIS 
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Spectrum generated epi-illumination images of pipettes loaded with free and 
encapsulated 4, 8, and 12 fmol IR800CW dye (1,2 and 3ul of 4 nM dye) as shown in 
figure 4.3. 
 
Figure 4.3        IRDye 800CW Pipette Standards for Phantom Mouse 
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Figure 4.4        Minimum Detection Limits with Epi-illumination 
To determine the limit of detection for the IRDye800CW loaded niosomes, the 
phantom mouse was imaged in the ventral position with a 12 fmol IRDye 800CW loaded 
niosome sample for 1 second with F1 aperture, high lamp, binning set at level 4 with epi-
illumination as shown in Figure 4.4. For comparison the phantom mouse was placed in 
the dorsal position and the same sample was imaged using trans-illumination, shown in 
figure 4.5. The sample emitted a signal of 2.6E9 photons/sec/cm
2
 when imaged for 5 
seconds F2 aperture, high lamp, binning at level 4. Results indicate the niosome and dye 
concentrations are adequate for pilot in vivo imaging studies. 
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Figure 4.5        Phantom Mouse Imaged Under Trans-illumination 
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5. Discussion and Future Direction 
5.1.0 Vesicle Design and Manufacturing 
Many vesicle designs have been developed to transport therapeutic agents to 
specific sites in the body. While no one design provides a solution for every application, 
techniques using bilayer membranes to entrap therapeutic agents have proven successful. 
Polymers provide vesicle stability, but the harsh conditions used for the polymerization 
process can be detrimental to the agent being entrapped. Amphiphiles made from 
peptides are easily metabolized in the body making them biocompatible. However, 
because the molecules can be broken down so easily, the vesicle life span is low, and 
spontaneous release of the entrapped drug can cause toxic dosage levels. In the niosome 
production, the use of synthetic non-ionic surfactants provides an economical and 
physiological advantage compared to traditional phospholipids used in liposome 
production. Because phospholipids have the tendency to oxidize over time, great care 
must be taken to ensure the product remains safe for use. Synthetic surfactants also have 
an advantage because surfactants derived from natural sources require extra processing to 
ensure there are no pathological contaminants. 
 The 200 nm size chosen for the niosome design provides an internal volume that 
can contain a substantial dosage of the therapeutic agent, yet is small enough to evade 
opsonization (coating of the vesicles by plasma proteins) and recognition by the 
reticuloendothelial system. The 200 nm size is large enough to eliminate the non-specific 
uptake of the vesicles through the process of cellular pinocytosis. The 200 nm size also 
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allows the vesicle to remain in suspension for an extended period of time. The addition of 
polyethylene glycol to the niosome (PEGylation) provides a mechanical boundary 
between vesicles. This steric stabilization further enhances the stability of the niosome 
suspension. The PEG chains also reduce the attachment of plasma proteins to the 
niosome membrane surface. This is a very important feature that has been shown by other 
groups to increase the circulation time of the vesicle in vivo. 
 Targeting specific endothelial cell surface receptors allows for intravenous 
delivery of the vesicles. This route delivers all of the vesicles to the blood where they will 
encounter the endothelial cells lining the vessel walls. CD44, an inflammatory receptor 
expressed by activated endothelial cells after cytokine exposure or physical injury, is the 
targeted receptor. The CD44 receptor is also present on many cancer cells and provides a 
method of delivering a therapeutic vesicle directly to the tumor. In addition to targeting 
CD44, ICAM-1 and VCAM-1, other inflammatory receptors expressed by endothelial 
cells were targeted, and binding of PEGylated immuno-niosomes (IN) with the three 
different receptors types was compared. We investigated nonspecific binding and the 
ability of the PEGylated immuno-niosomes to bind fixed and live endothelial cells. We 
showed by confocal microscopy that PEGylated immuno-niosomes can be internalized by 
the endothelial cell when they bind to the CD44 receptor (figure 3.11). This suggests that 
the targeting scheme is capable of delivering therapeutics to specific cells. 
 Two methods were used to stimulate the upregulation of inflammatory cell 
surface receptors. One method was the exposure of the cell to the pro-inflammatory 
cytokine, tumor necrosis factor alpha (TNF-α). This is a well described process that has 
been used in vitro to mimic the natural process of inflammation. An injury model was 
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used to investigate the capacity of the PEGylated immuno-niosomes to target cells that 
have experienced physical trauma. 
 The concentration of atorvastatin encapsulated in immuno-niosomes was 
determined using thin layer chromatography (TLC). It was found that two solvent 
systems were required to separate all the immuno-niosome components from the 
atoravastatin. The atorvastatin-loaded immuno-niosomes were pre-processed prior to 
TLC separation to remove the surfactant and to concentrate the sample. Using known 
atorvastatin concentrations, a standard curve was created. We determined that this TLC 
separation method gave us the ability to accurately determine concentration as indicated 
by the linear correlation coefficient (R
2
) of 0.9898 between the known and unknown 
atorvastatin concentrations. 
 In the previous immuno-niosome design developed in our lab by Hood et al., 
cyanuric chloride was used to link the Tween 61 and CD44 antibody used to target the 
niosome to the endothelial cells. In the work reported here, polyethylene glycol with 
cyanuric chloride linking chemistry was added to this previous design, creating the 
PEGylated immuno-niosome (figure 1.0). The linker chemistry was used to attach and 
functionalize the PEG to the head group of the Tween 61 surfactant. The size and amount 
of PEG used was based on previous liposome designs [12-15] and the results from the 
fixed cell binding experiments (figures 3.0 and 3.1) which showed improved binding of 
PEGylated CD44-IN as compared with CD44-IN to the activated endothelial cells. The 
current PEGylated INs contain PEG surfactant on both the interior and exterior of the 
vesicle. The immuno-niosome design can be further modified by incubating niosomes 
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with PEGylated micelles to created PEGylated immuno-niosomes with the PEG only on 
the immuno-niosome outer surface. 
 Therapeutic agent or dye entrapment occurs during the thin film hydration 
process. This process time was extended from one to four hours, keeping other conditions 
constant, to provide a bulk solution that was more homogenous than previously obtained. 
Use of a more homogenous bulk solution lessened the previously seen fouling of the 
polycarbonate membranes used for vesicle extrusion. With a bulk solution hydration time 
of one hour, the membranes in the extruder needed to be replaced after four passes. When 
the hydration time of the bulk solution was extended to two hours, eight-ten passes 
through the extruder could be accomplished before the membranes fouled. When the 
hydration time of the bulk solution was extended to four hours, the number of passes 
before the membranes fouled approached 20. The high number of passes translates to 
better size control of the vesicles and lower numbers of vesicles becoming entrapped in 
the extruder membranes (less waste). 
 After bulk solution extrusion, the encapsulated and free therapeutic agent or dye 
was separated using size exclusion chromatography. This type of separation results in 
some sample loss and sample dilution. Under theoretical conditions, separation of 
vesicles based on size is based on the assumption that there are no entrance or exit effects 
from the column. However, empirically we showed that when the sample was loaded on 
the column, the interaction of the bulk solution and the entrance region caused back 
mixing (figure 2.8). The sample volume loaded on the column was reduced from 2 ml to 
500 µl (figure 2.9). The reduction in sample volume loaded resulted in symmetric elution 
profiles where the vesicle size correlated with the elution fraction. To determine PEG 
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incorporation efficiency in the niosomes, the bulk solution was spiked with free PEG. 
The spiked sample was loaded and eluted through the column. The resulting elution 
profile showed an extra peak that was not present in samples that were not spiked with 
free PEG. These results indicated that the PEG modified surfactant was incorporated in 
the PEGylated niosome (results not shown). 
 A difference in PEGylated niosome versus niosome size distribution was 
determined using dynamic light scattering. The addition of PEG to a vesicle can alter the 
niosome solution viscosity and change its light absorbance properties which will affect 
data collected using dynamic light scattering. To minimize the effects of the PEG on the 
PEGylated niosome size distribution measurements, the samples were diluted with 0.01 
M phosphate buffered saline, to maintain osmolarity and prevent PEGylated niosome 
rupture. The large dilution of the PEGylated niosome sample caused the sample viscosity 
to approach pure solvent (phosphate buffered saline). The size distribution changed by 
only 4 nm, indicating that the PEG did not affect PEGylated niosome size distribution 
and that the original measurements were valid. The PEGylated niosome size distribution 
was also measured using transmission electron microscopy (figures 2.17 and 2.18) and 
flow cytometry (figures 2.11 and 2.12, tables 2.0 and 2.1). The PEGylated niosome size 
distribution supports the original measurements using dynamic light scattering (figure 
2.13). 
5.2.0 Experimental Conclusions 
 The binding efficiency of the PEGylated and non-PEGylated immuno-niosomes 
to tumor necrosis factor alpha (TNF-α)-activated endothelial cells was compared. The 
endothelial cells were plated in black/clear bottom multiwell culture plates. 5,6-
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Carboxyfluorescein was encapsulated in the PEGylated CD44-IN and CD44-IN to 
visualize binding to the endothelial cells. To prevent the endothelial cell surface receptors 
from being internalized or recycled over the two hour experimental time course, the cells 
were fixed prior to incubation with the PEGylated CD44-IN or CD44-IN. Binding of the 
PEGylated CD44-IN to activated endothelial cells was increased 17% over binding of the 
CD44-IN to activated endothelial cells (figures 3.0, 3.1, table 3.0). These data 
demonstrate that PEGylation of the immuno-niosomes improves specific binding to 
activated endothelial cells. 
 Next, experiments were conducted to determine the non-specific binding of the 
PEGylated immuno-niosomes to live endothelial cells. Fluorescent dye was encapsulated 
in the PEGylated CD44-IN, VCAM-1-IN and ICAM-1-IN to visualize binding. Non-
specific binding of the PEGylated CD44-IN, VCAM-1-IN and ICAM-1-IN to unactivated 
endothelial cells was measured. It was determined that non-specific binding was linear 
over the four hour time course (Figure 3.2). These data demonstrate that non-specific 
binding of the PEGylated IN to the unactivated endothelial cells was not antibody 
dependent. 
Next, experiments were conducted to determine the interaction of the PEGylated 
immuno-niosomes with live endothelial cells. Fluorescent dye was encapsulated in the 
PEGylated CD44-IN, VCAM-1-IN and ICAM-1-IN to visualize binding. The endothelial 
cells were activated with TNF-α for 24 hours prior to incubation with the PEGylated IN 
to induce an inflammatory response. Specific binding of the PEGylated CD44-IN, 
VCAM-1-IN and ICAM-1-IN to the activated endothelial cells was measured. It was 
determined that all three PEGylated IN had similar binding to the activated endothelial 
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cells over the four hour time course (Figure 3.3). These data suggest that the use of 
antibodies on the PEGylated IN that target CD44 is as effective as those that target 
VCAM-1 or ICAM-1.  
Next, experiments were conducted to confirm uptake of the PEGylated immuno-
niosomes by activated endothelial cells. Fluorescent dye was encapsulated in the 
PEGylated CD44-IN, VCAM-1-IN and ICAM-1-IN to visualize binding and uptake to 
activated endothelial cells using a confocal microscopy. The images captured provided 
confirmation that the immuno-niosome payload was internalized by the endothelial cells 
(Figures 3.7-3.13). This was a major accomplishment that had not been seen before using 
the vesicle design and antibody combination.  
Next, experiments were conducted to determine the interaction of the PEGylated 
immuno-niosomes with physically injured endothelial cells using confocal microscopy. 
The cells were injured 24 hours prior to incubation with 5,6-carboxyrhodamine loaded 
immuno-niosomes that were conjugated with CD44 or ICAM antibodies. The results 
indicated the immuno-niosomes can target endothelial cells that have sustained trauma 
from a physical injury (Figures 3.4, 3.5 and 3.6, Table 3.1). This is another important 
finding and the results suggest that injuries sustained from battlefield wounds can be 
targeted by therapeutic immuno-niosomes. This also means that the immuno-niosome 
could deliver therapeutic agents to venous grafts after coronary surgery.  
5.3.0 Future Directions 
 Experiments designed to determine the performance of the PEGylated immuno-
niosomes in vivo have been approved and funded through the Signature Interdisciplinary 
Program In Cardiovascular Research (SIPCVR), a pilot grant program funded by USF 
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Health. The proposed experiments will assist us in determining the bio-distribution of the 
CD44, ICAM or VCAM conjugated immuno-niosomes in apolipoprotein E knockout 
(apoE -/-) mice and wild type control mice (C57BL/6). The data will also give insight to 
the pharmacokinetics (described in section 1.1.1) of the PEGylated immuno-niosomes in-
vivo. The experimental design is to target sites of vascular inflammation caused by 
atherosclerosis in the apo-E -/- mice. The mice will be injected with fluorescent dye 
loaded immuno-niosomes, fluorescent dye loaded niosomes without antibodies or free 
dye. Near infrared fluorescent dye, IRDye 800cw will be used so the animals can be 
imaged live using the Xenogen IVIS Spectrum (described in section 4.2.0). The organs 
will be imaged whole and then sectioned to give greater detail of the interactions and 
binding of the immuno-niosomes with organs and cells. 
 The next experiments will be based on the information gained from, the pilot 
study. To improve endothelial cell binding in large arteries, modification to the immuno-
niosome design will be made using the functionalized cholesterol (described in section 
2.3.2) and a biotinylated PEG to conjugate both antibodies and selectins, respectively. 
These modifications will provide a design that will allow the immuno-niosome to attach 
with low affinity to the vessel wall via selectin binding and then roll to a site of 
inflammation where the antibody can bind with high affinity, mimicking leukocyte 
binding. 
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Appendix A: Transmission Electron Microscopy Notes 
note 1: Embedding resin is made by combining 13.75 grams of Embed 812, 8.5 grams 
Araldite502 and stirring thoroughly  without introducing bubbles. Then the resin 
is activated by stirring in as before 27.5 grams of DDSA and 0.7-0.9 grams of 
DMP-30. 
note 2: The grids are prepared by sonicating them in technical grade acetone for one 
minute followed by reagent grade acetone for one minute and finally in 95% 
ethanol. Decant ethanol and invert petri dish over filer paper until grids fall from 
the dish and have completely dried.  
note 3: To make 50 ml of UA stain heat 50 ml DiH2O to 60 degrees Celsius. Under fume 
hood add 0.5 grams of UA (CAUTION)to the heated DiH2O. Allow to cool and 
do not agitate before use. 
note 4: Simple lead citrate is prepared by adding 0.01-0.04 grams of lead citrate to 10ml 
of freshly boiled and cooled H2O in a screw top vial. Then add 0.1ml of 10N 
NaOH and shake until lead dissolves. 
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